# Table of Contents

Introduction .................................................................................................................................................. 5
Prescribing in the Perinatal Period ........................................................................................................... 6
Resources .................................................................................................................................................. 8
Perinatal Attention-Deficit/Hyperactivity Disorder (ADHD) .............................................................. 14
    Care Guide ......................................................................................................................................... 15
    Medications ...................................................................................................................................... 16
Peripartum Agitation ................................................................................................................................. 17
    Care Guide ......................................................................................................................................... 18
    Medications ...................................................................................................................................... 21
Perinatal Anxiety ....................................................................................................................................... 24
    Care Guide ......................................................................................................................................... 25
    Medications ...................................................................................................................................... 26
    Resources ........................................................................................................................................ 27
Assessing Safety ....................................................................................................................................... 28
    Assessment of Safety Risk in Perinatal Populations ...................................................................... 29
    Intimate Partner Violence Risk Assessment .................................................................................. 34
    Assessment of Risk for Harm of Infants and Children ................................................................. 40
Perinatal Bipolar Disorder ......................................................................................................................... 44
    Care Guide ......................................................................................................................................... 45
    Medications ...................................................................................................................................... 46
    Resources ........................................................................................................................................ 47
Perinatal Cannabis Use .............................................................................................................................. 48
    Care Guide ......................................................................................................................................... 49
    Resources ........................................................................................................................................ 52
Perinatal Depression .................................................................................................................................. 53
    Care Guide ......................................................................................................................................... 54
    Medications ...................................................................................................................................... 55
    Resources ........................................................................................................................................ 56
Perinatal Eating Disorders ......................................................................................................................... 57
    Care Guide ......................................................................................................................................... 58
    Resources ........................................................................................................................................ 59
Family Assessment ................................................................................................................................. 60
    Care Guide ......................................................................................................................................... 61
    Resources ........................................................................................................................................ 62
Hormones and Mood ............................................................................................................................... 63
    Care Guide ......................................................................................................................................... 64
Infertility .................................................................................................................................................... 65
    Care Guide ......................................................................................................................................... 66
    Resources ........................................................................................................................................ 68
Perinatal Obsessive-Compulsive Disorder (OCD) ................................................................. 69
  Care Guide ....................................................................................................................... 70
  Resources ......................................................................................................................... 72

Perinatal Posttraumatic Stress Disorder (PTSD) ............................................................... 73
  Care Guide ....................................................................................................................... 74
  Resources ......................................................................................................................... 76

Pregnancy Loss .................................................................................................................... 77
  Care Guide ....................................................................................................................... 78
  Resources ......................................................................................................................... 81

Postpartum Psychosis ......................................................................................................... 83
  Care Guide ....................................................................................................................... 84
  Medications ....................................................................................................................... 86

Perinatal Schizophrenia ...................................................................................................... 87
  Care Guide ....................................................................................................................... 88
  Medications ....................................................................................................................... 90

Sleep in the Perinatal Period ............................................................................................... 91
  Care Guide ....................................................................................................................... 92
  Medications ....................................................................................................................... 93
  Resources ......................................................................................................................... 95

Substance Use in Pregnancy ............................................................................................... 96
  Care Guide ....................................................................................................................... 97
  Resources ......................................................................................................................... 98
  Selecting a Medication for Opioid Use Disorder in Pregnancy ......................................... 99
(877) 725-4666

UW Perinatal Psychiatry Consultation Line (Perinatal PCL), a Free Consult Line for Providers

The UW Perinatal Psychiatry Consultation Line (Perinatal PCL) is a free state-funded program providing perinatal mental health consultation, recommendations, and referrals for providers caring for pregnant or postpartum patients.

HOW DOES IT WORK?

Call 877-725-4666 (PAL4MOM), available weekdays 9am - 5pm
Complete a brief intake
Consult with a UW perinatal psychiatrist (usually immediately, or within 1 business day)
Receive written documentation of recommendations and resources

WHO CAN CALL?

Any provider in Washington State who cares for pregnant or postpartum patients.

WHAT KIND OF QUESTIONS CAN I CALL ABOUT?

We consult on any behavioral health-related questions for patients who are pregnant, in the first year postpartum, or who have pregnancy-related complications (e.g. pregnancy loss, infertility). Topics may include:

- Depression, anxiety, other psychiatric disorders (e.g., bipolar disorder, post-traumatic stress disorder), substance use disorders, or co-occurring disorders
- Pregnancy loss, complications, or difficult life events
- Weighing risks and benefits of psychiatric medication
- Non-medication treatments
- Local resources & referrals
- Guidance on implementing mental health screening at your workplace

WHO PROVIDES THE TELEPHONE CONSULTATION?

Faculty members in the UW Department of Psychiatry and Behavioral Sciences with expertise in perinatal mental health.
Introduction

This care guide is intended to help prenatal, primary care, and mental health providers screen for, diagnose, and treat pregnant and postpartum individuals with mental health problems. The guide is based on current evidence in the literature, as of the time of writing. We have attempted to distill current knowledge into focused, practical points. The guide is divided into modules, each covering a particular diagnosis/set of disorders or important topic in perinatal mental health.

Modules include:
- Overviews of disorders, including recommended approaches to diagnosis, differential diagnosis, and treatment
- Summaries and approaches to other concerns related to the perinatal period or reproductive hormonal effects on mental health
- Free-to-reproduce rating scales useful in indicating need for further diagnostic assessment and assessing response to treatment
- A general approach to prescribing during the perinatal period
- Organized, current evidence-based information about medications, including dosing, side effects, and effects/risks during pregnancy and lactation
- References and resources for providers and for patients

Care guide modules were written by PAL for Moms psychiatrists, as well as guest experts on specific topics. Modules were based on current literature (obtained by PubMed searches) and databases (e.g. Reprotox, LactMed). Each module was peer-reviewed by the PAL for Moms psychiatrist group:

- Amritha Bhat MD
- Deborah Cowley MD
- Carmen Croicu MD
- Aba Nduom MD
- Katherine Palm-Cruz MD
- Laurel Pellegrino MD
- Ramanpreet Toor MD
- Kelly Wurzel MD

Additional contributors to and reviewers of this guide include: Nadejda Bespalova, MD, Aubrey Demajh, MD, Alicia Kerlee, MSW, Laura Laplante, MD, Zoe Renner, MD, Megan Riddle, MD, and Cummings Rork, MD.

We hope that this guide is helpful and welcome any feedback. Please also feel free to call us at PAL for Moms (1-877-PAL4MOM/ 1-877-725-4666) with any questions that you have about individual patients/clinical situations, general issues, or resources and referrals.
Prescribing in the Perinatal Period

Most Perinatal PCL calls include questions about effects of medications and about prescribing during pregnancy and breastfeeding. Each Perinatal PCL care guide module that focuses on a specific disorder provides the most up to date information, as of the time of writing, about medications used to treat that disorder. In this section, we outline general guidelines for prescribing during the perinatal period and provide some resources to use in looking up the most recent information, and in finding medication fact sheets to give to your patients. The guidelines below reflect our overall approach, which is to use the lowest number and dosages of medications possible, while effectively treating the psychiatric disorder(s).

What are some general rules of thumb about prescribing during the perinatal period?

1. **Consider risks during pregnancy whenever prescribing medication for someone of childbearing potential.** About 50% of pregnancies are unplanned. Considering, and informing people of childbearing potential about, risks of their medication(s) during pregnancy helps to maximize prescribing of safer medications and avoid patients' suddenly discontinuing needed medication if they find out they are pregnant.

2. **Make any medication changes before pregnancy if possible.** This minimizes the number of exposures for the baby and maximizes stability for the parent. Changing a newer medication with less data regarding safety in pregnancy to an older medication with more safety data can be done before pregnancy, if desired. Making this change once the patient is already pregnant involves exposing the baby to two medications instead of one and potentially causing worsening of the parent's psychiatric condition.

3. **Remember that an untreated/undertreated psychiatric disorder also poses risks to the parent and the baby.** Untreated/undertreated psychiatric disorders pose significant risks for parents and babies. For example, perinatal depression is associated with higher rates of preterm birth, low birth weight, problems with attachment and bonding, and increased rates of psychiatric disorders in childhood and adolescence. For this reason, it is important to treat psychiatric disorders effectively during the perinatal period.

4. **Ideally, the patient should be psychiatrically stable for at least 3 months before trying to conceive.** Although this is not always possible, it decreases the risk of relapse and exposure of the baby to risks of untreated/undertreated psychiatric illness.

5. **Avoid polypharmacy whenever possible.** Prescribing the fewest medications possible to effectively treat the patient's psychiatric disorder reduces exposures for the baby. Reviewing the need for each medication is especially important when someone is taking multiple medications and/or more than one medication in a class (e.g., two or more antidepressants, two or more antipsychotics, multiple antianxiety/hypnotic medications, etc.)

6. **Avoid Depakote.** Depakote (valproic acid) is a commonly prescribed mood stabilizer for patients with bipolar disorder. Depakote is a known teratogen (rate of malformations elevated in all dosage ranges and 25% at doses above 1450 mg/day) and is associated with significantly decreased IQ in children exposed in utero.
7. **Optimize non-medication treatments.** At all times, and especially during the perinatal period, we want to maximize the use of evidence-based non-medication treatments such as psychotherapy. Most people with mild to moderate depression and anxiety respond to evidence-based psychotherapy and do not need medication if psychotherapy is available. Even if someone requires medication for effective treatment of their condition, non-medication treatments can help minimize numbers and dosages of medications and increase effectiveness of treatment.

8. **If you are thinking of stopping your patient’s psychotropic medications because they are pregnant, please call us first.** Discontinuing medications abruptly can precipitate relapse (another exposure for the baby and risk for the parent). Also, stopping some medications can cause withdrawal symptoms that are potentially dangerous (e.g., benzodiazepines) or unpleasant (e.g., antidepressants). We would be happy to help you sort out which medications to discontinue and safe tapering schedules.

9. **Prescribing during the perinatal period requires a risk-risk discussion.** Informed consent during the perinatal period involves collaborating with the patient in discussing and weighing risks of medication for the fetus/baby, risks of the psychiatric disorder, and possible alternative treatments.

10. **Use a patient-centered and team approach.** In addition to collaborative decision-making with, and support of, the patient, this includes involving family members and communicating with other care providers. It is important to educate the partner and/or family members about the risks and benefits of treatment as well as warning symptoms of relapse. Communication with obstetric and pediatric providers minimizes the patient's hearing conflicting opinions and being confused and concerned.

References and resources:


InfantRisk apps for healthcare providers and parents about safety of medications during pregnancy and breastfeeding. [https://www.infantrisk.com/infantrisk-center-apps](https://www.infantrisk.com/infantrisk-center-apps)


Reprotox database about medications during pregnancy, breastfeeding, and development. Requires subscription. [https://reprotox.org/](https://reprotox.org/)

MotherToBaby fact sheets for parents regarding risks of drugs (including non-prescribed drugs) during pregnancy and breastfeeding. [https://mothertobaby.org/fact-sheets/](https://mothertobaby.org/fact-sheets/)
Resources
Psychiatry Consultation Services for Washington State Healthcare Providers

**Psychiatry Consultation Line (PCL)**
for prescribing providers with adult psychiatry and/or addictions questions
877-WA-PSYCH (877-927-7924) | pclwa@uw.edu
Staffed 24/7
www.pcl.psychiatry.uw.edu

**Partnership Access Line (PAL)**
for primary care providers with child and adolescent psychiatry questions
866-599-7257 | paladmin@seattlechildrens.org
8am-5pm, Monday-Friday (excluding holidays)
www.seattlechildrens.org/PAL

**Perinatal Psychiatry Consultation Line (PPCL)**
for providers with behavioral health questions related to pregnancy and postpartum
877-PAL4MOM (877-725-4666) | ppcl@uw.edu
9am-5pm, Monday-Friday (excluding holidays)
www.perc.psychiatry.uw.edu/perinatal-pcl

**Psychiatry & Addictions Case Conferences (UW PACC-ECHO)**
for providers interested in didactic presentations and case-based learning
uwpacc@uw.edu
12:00-1:30 pm, Thursdays
ictp.uw.edu/programs/uw-pacc
General Resources for Providers

**LactMed**  
Peer-reviewed database that provides data on the safety of medications during breastfeeding.  

**InfantRisk Center**  
Phone app and call center that provide evidence-based data on medication and drug safety in pregnancy and breastfeeding.  
[https://www.infantrisk.com/](https://www.infantrisk.com/)

**Massachusetts General Hospital Center for Women's Mental Health**  
A reproductive psychiatry resource and information center.  
[https://womensmentalhealth.org/](https://womensmentalhealth.org/)

**Reprotox**  
Database with information about medications during pregnancy, breastfeeding, and development. Requires subscription.  
[https://reprotox.org/](https://reprotox.org/)

Statewide UW Resources for Providers

**UW Perinatal Psychiatry Consultation Line (Perinatal PCL): (877) 725-4666**  
Telephone consultation, recommendations, and referrals for healthcare providers caring for patients with behavioral health disorders during pregnancy and postpartum. Available weekdays 9 am-5 pm.  
[https://perc.psychiatry.uw.edu/perinatal-pcl](https://perc.psychiatry.uw.edu/perinatal-pcl)

**UW Psychiatry Consultation Line (PCL): (877) 927-7924**  
Telephone consultation and recommendations for providers caring for adult patients (18+) with mental health and/or substance use disorders. Available 24/7 for prescribers, weekdays for non-prescribers.  
[https://pcl.psychiatry.uw.edu/](https://pcl.psychiatry.uw.edu/)

**Partnership Access Line (PAL): (866) 599-7257**  
Telephone consultation and recommendations for primary care providers caring for children and adolescents with behavioral health disorders. Available weekdays 8 am-5 pm.  
[https://www.seattlechildrens.org/healthcare-professionals/access-services/partnership-access-line/](https://www.seattlechildrens.org/healthcare-professionals/access-services/partnership-access-line/)

**UW Psychiatry and Addictions Case Conference-ECHO (UW PACC)**  
A free, weekly teleconference that includes an educational presentation by UW psychiatrists and case presentations. Archive of past presentations can be searched for presentations on the perinatal period.  
[https://ictp.uw.edu/programs/uw-pacc](https://ictp.uw.edu/programs/uw-pacc)
Statewide Perinatal Mental Health Resources

**UW Perinatal Telepsychiatry Clinic**
A telepsychiatry clinic for perinatal patients that provides one-time evaluations (rather than ongoing treatment). Referring providers receive a follow-up note with recommendations.
https://perc.psychiatry.uw.edu/perinatal-psychiatry-virtual-clinic/

**Perinatal Support Washington**
Organization offers a warm line, perinatal mental health directory, provider training, and more.
https://perinatalsupport.org/

**Swedish Center for Perinatal Bonding and Support**
Center offers outpatient reproductive psychiatry and a day treatment program for people with perinatal mood disorders.
https://www.swedish.org/locations/center-for-perinatal-bonding-and-support

**Northwest Infant Survival and SIDS Alliance**
Emotional support for those who are affected by pregnancy loss and infant loss.
https://nwsids.org/

**Prevention and Treatment of Traumatic Childbirth (PATtch)**
An organization that offers information and trainings about traumatic births.
http://pattch.org/

National Perinatal Mental Health Resources

**Perinatal Support International (PSI)**
Free online support groups, and information and resources for parents and professionals.
https://www.postpartum.net/

**RESOLVE: (866) 668-2566**
A warm line for support around infertility, IVF, adoption, and miscarriage.
https://resolve.org/support/helpline/

**Mother To Baby: (866) 626-6847**
Information center for community members that provides free safety data about medications and drugs during pregnancy and breastfeeding. Fact sheets about medications are also available.
https://mothertobaby.org/

**Maternal Mental Health Hotline: (833) 852-6262**
Free, 24/7 hotline for people who are pregnant and new parents. Offers emotional support and referrals to resources in English and Spanish and interpreter services in 60 languages.
https://mchb.hrsa.gov/national-maternal-mental-health-hotline
Perinatal Substance Use Resources

**Washington Recovery Helpline: (866) 789-1511**
24/7 helpline for substance use referrals and support.
http://www.warecoveryhelpline.org/

**Swedish “Yes We Can” Consultation Line:**
(833) 937-9326
Provider to provider psychiatry consultation line for providers in WA state with questions about perinatal substance use disorders

**The First Clinic**
Legal aid to prevent substance-use-related family separation for families with a baby in the hospital
https://thefirstclinic.org/

Parent-Child Assistance Program (PCAP)
Free case management program for pregnant and parenting people with substance use disorders.
https://pcap.psychiatry.uw.edu/

Pregnant and Parenting Women (PPW) Program
Residential and outpatient SUD treatment for Medicaid-eligible pregnant and parenting people.
https://www.hca.wa.gov/assets/program/factsheet-ppw-services.pdf

Chemical-Using Pregnant Women (CUP) Program
An inpatient treatment program for Medicaid-eligible people who are pregnant.
https://www.hca.wa.gov/health-care-services-supports/apple-health-medicaid-coverage/chemical-using-pregnant-women

Statewide General Mental Health Resources

**Mental Health Crisis Lines: 988**
Look up your county's crisis line or call 988 to be connected to mental health crisis services
https://www.hca.wa.gov/free-or-low-cost-healthcare/i-need-behavioral-health-support/mental-health-crisis-lines

**Designated Crisis Responders (DCRs) List**
A contact list for designated crisis responders (DCRs) in each of the 39 counties in Washington.

**Washington Counselors of Color Network**
A database of multicultural counselors and counselors of color in Washington state.
https://www.multiculturalcounselors.org/

**WA Mental Health Referral Service for Children and Teens:**
(833) 303-5437
A free service that connects families with mental health providers.
Using WA Mental Health Referral Service for Children/Teens (seattlechildrens.org)

**Ingersoll Gender Center Provider Directory**
A database of gender- affirming health care providers in WA, searchable by mental health and reproductive health.
https://ingersollgendercenter.org/ingersoll-directory/
Other Perinatal Resources

Within Reach: (800) 322-2588
Hotline, online database, and free care coordination to help families across Washington navigate health and social service systems.
https://withinreachwa.org/

First Steps Maternal and Infant Care
This program assists people who are pregnant and on Medicaid in getting access to health and social services.

Child Care Aware of Washington: (800) 446-1114
Hotline and database provide free tailored referrals for childcare and early learning to anyone in Washington state.
https://childcareawarewa.org/

Nurse-Family Partnership
A free home visiting program that provides visits by a nurse to qualifying families from pregnancy until a child is two years old. Program is available in many Washington counties.
https://www.nursefamilypartnership.org/

Early Head Start
https://www.dcyf.wa.gov/services/earlylearning-childcare/eceap-headstart

National Diaper Bank Network
Nonprofit that works to address diaper need. Maintains a database of community-based diaper banks, which distribute free diapers, that includes eight diaper banks across WA state.
https://nationaldiaperbanknetwork.org/

Mount Sinai Parenting Guides
Parent-facing guides about infant and toddler development and behavior
Parent Guides | Mount Sinai Parenting Center

Mother’s Mind
Learn about understanding and coping with intrusive thoughts during the postpartum period.
https://www.momsmindmatters.com/
Perinatal Attention-Deficit/Hyperactivity Disorder (ADHD)

Laurel Pellegrino, MD
Perinatal ADHD

**Prevalence:** 3-4% of adults (prevalence unchanged during pregnancy and postpartum)

**Common Comorbidities:** Mood disorder (38%), anxiety disorder (47%), substance use disorder (15%) disorder

**Medication Use:** Roughly 20% of pregnant people choose to continue ADHD meds throughout the pregnancy

---

### First, confirm the diagnosis:
- Administer Adult ADHD Self-Report Scale (ASRS)—5 min, positive result warrants further consideration
- Age of onset, school history
- Impairment in two or more domains
- Rule out other causes: sleep apnea, anxiety, depression, substance abuse

### Next, assess level of impairment:
- Have they ever been off medications in the past? What happened? Do they need medications to function at work or at home?
- Are comorbidities worse off of medication (e.g. substance use)? Are they more impulsive or accident-prone off meds (e.g. driving)?

### Mild
- Discontinue medication
- Optimize non-pharmacologic strategies

### Moderate
- Assess for comorbidities
- Optimize non-pharmacologic strategies
- Consider bupropion vs prn stimulant

### Severe
- Assess for comorbidities
- Continue stimulant at lowest effective dose (skip days when possible)
- Monitor maternal BP and weight gain
- Monitor fetal growth
- Optimize non-pharmacologic augmentation strategies

---

### Possible pregnancy outcomes associated with untreated ADHD:
- miscarriage
- preterm birth
- NICU admissions
- poor maternal nutrition & decreased prenatal vitamin use

### Non-pharmacologic strategies for mild, moderate, and severe ADHD:
- Psychoeducation
- Cognitive Behavioral Therapy (CBT) for ADHD
- Coaching
- ADHD Support groups
- Reduce workload or other workplace accommodations if possible
- Use public transportation if driving concerns

---

**Possible pregnancy outcomes associated with untreated ADHD:**

- miscarriage
- preterm birth
- NICU admissions
- poor maternal nutrition & decreased prenatal vitamin use
## ADHD Medications in Pregnancy

<table>
<thead>
<tr>
<th></th>
<th>Early Pregnancy</th>
<th>Late Pregnancy</th>
<th>Breastfeeding?</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Methylphenidate</strong></td>
<td>No consistent association with overall defects (~6700 exposures); possible small increased risk of cardiac septal defects (NNH estimates range from 92-333); possible increased risk spontaneous abortions.</td>
<td>Small increased risk of preterm birth. Possible increased risk of preeclampsia, SGA, placental abruption, low Apgar score, NICU admission, CNS disorders, induced terminations</td>
<td>Low levels in breastmilk, undetectable in infant serum. Limited data without adverse effects.</td>
</tr>
<tr>
<td><strong>Prescribed amphetamines</strong></td>
<td>No consistent association with malformations (~5600 exposures).</td>
<td>Small increased risk of preterm birth and preeclampsia. Possible increased risk of SGA, placental abruption, NICU admission, CNS disorders.</td>
<td>Infant dose 5-15% maternal dose. Very limited data without adverse effects.</td>
</tr>
<tr>
<td><strong>Bupropion</strong></td>
<td>No consistent association with malformations (~2300 exposures).</td>
<td>No adverse effects (small studies)</td>
<td>Nursing infant exposed to 2% maternal dose; 2 case reports of seizures at 6 months</td>
</tr>
<tr>
<td><strong>Atomoxetine</strong></td>
<td>No consistent association with malformations (~450 exposures)</td>
<td>Mixed evidence (~700 exposures)</td>
<td>Unknown</td>
</tr>
<tr>
<td><strong>Guanfacine</strong></td>
<td>Too few exposures to say (~30)</td>
<td>Low birth weight (very small studies)</td>
<td>Unknown</td>
</tr>
<tr>
<td><strong>Clonidine</strong></td>
<td>No consistent association with malformations based on data from women with HTN</td>
<td>Reduced fetal growth</td>
<td>Excreted in breast milk. Adverse events reports (hypotonia, drowsiness, apnea, seizure)</td>
</tr>
</tbody>
</table>
Peripartum Agitation

Zoe Renner, MD
## Peripartum Agitation: Overview of Basic Principles

### What is Agitation?

- **Definitions:**
  - Combative and aggressive behavior, physical restlessness, or extreme irritability (1).
  - Increased verbal or physical activity accompanied by increased arousal and decreased functionality.

- **Agitation in pregnancy should be considered an obstetric emergency due to risk of harm to mother and/or baby/fetus.**

- **Risks of untreated agitation are generally considered greater than one-time medication intervention.**
  - Agitation associated with complications such as preterm delivery, placental abnormalities, low birth weight, postnatal death, spontaneous abortion (4).
  - Leaving alcohol withdrawal untreated leads to increased risk for preterm birth and low birth weight (1).
  - One-time dose of anti-psychotic and/or benzo generally considered to be low risk.

### What is Causing the Agitation? -- Determine Likely Underlying Etiology

- **Rule out Underlying Medical Condition**
  - Delirium due to medical condition, amniotic or venous thromboembolism, pre-eclampsia/eclampsia, hyperthyroidism, trauma, infection, among others.

- **Psychiatric Illness**
  - New onset vs exacerbation/decompensation of existing condition.
  - Abrupt discontinuation of psychotropic medications due to concern over fetal risk (1).
  - Post-partum psychosis
  - “Personality” characteristics

- **Drug Intoxication or Withdrawal**
- **Pain**
- **Traumatic Brain Injury (TBI)**

### Step 1: Verbal De-escalation and Behavioral Re-direction

- **Safety First**
- **Respect Personal Space**
- **Speak Slowly in Calm, Low Voice**
- **Be Concise**
- **Be Present and Genuine**
- **Establish Trust**
- **Listen**
- **Validate**
- **Provide Accurate Reflections**
- **Normalize Reactions**
- **Identify Wants/Feelings**
- **Offer Choices/Options**
- ‘Agree’ or ‘Agree to Disagree’
- **Do Not be Provocative**

### Examples of Verbal Strategies

- What helps you at times like this?
- I think you would benefit from medication, or I think you need a medication.
- I know you feel like _____ and that must be tough. Others in this predicament have also felt this way. In my experience, I have found that ______.
- Offer warm blanket, food, etc.

### Ensure safety of yourself, staff & scene (1)

- Ensure patient and the room are free of safety hazards/weapons.
- Remain at a safe distance from patient with clear exit from room.
- Alert appropriate security personnel and/or have mechanism for alerting additional staff/security.
Step 2: General Principles of Pharmacological Interventions

- Goal: Address safety and allow for complete assessment/treatment of underlying cause.
- Choice of medication should ideally be suited to underlying etiology of agitation.
- When treating pharmacologically:
  - Offer PO first to honor autonomy.
  - Use IM/IV only if refusal of PO, Danger to Self (DTS) and/or Danger to Others (DTOs).
  - If does not have decisional capacity (ex. floridly delusional), okay to start with IV option.
- General approach:
  - Start with PRN option.
  - Recommend scheduling medications if persistent, regularly occurring agitation.
  - Taper/Discontinue once agitation has resolved for a few days.
- Consider onset of action
  - IV works the fastest: approximately 5-20 minutes.
  - PO generally takes at least 30 mins-1 hour.
- Put in a not to exceed (NTE) in order.
- Never feel like you have to order a medication immediately. If unsure, go lay eyes on the patient.
- Pregnancy specifics:
  - Limit medications as able (ex. choose already prescribed medication).
  - Potential options: diphenhydramine, haloperidol, olanzapine, lorazepam.
  - One-time doses of benzodiazepines and anti-psychotics are generally considered low risk and not associated with an increased risk in congenital malformations.
  - Contra-indicated: valproic acid

Step 3: Restraints: Last resort intervention only during pregnancy

- Use only if imminent risk to 1.) mother 2.) fetus/newborn 3.) staff or others AND failure of prior interventions/least restrictive options.
- DO: Use least restrictive options possible (fewer restraints the better). Continue frequent monitoring of patient/vital signs/fetal heart tones while in restraints. Ensure adequate comfort, hydration, nutrition, and medical stability throughout process. Limit/end restraints as much as possible.
- DO NOT USE: abdominal restraints, restraints that increase risk of falling forward (wrist restraints behind the back), four-point restraints, restraints during labor & delivery, use out of convenience or punishment (6).
- 20 weeks+: Place pregnant patient partway to the left with support under the right hip – right hip should be 10-12 cm off the bed with supporting pillows/blankets.
  - Do not restrain in supine position or on right side due to risk of inferior vena cava compression syndrome (hypotension, tachycardia, fetal distress due to compression vena cava, blocking flow of venous blood to the heart; 5,6).

*Be mindful of implicit bias and thoughtful about escalation of interventions*
Pharmacological Interventions: Specific Medications*

- Choose medication based on most likely underlying cause of agitation when possible (ex. lorazepam for alcohol withdrawal). Limit medications as able (ex. choose already prescribed medication).

- **Mild: PO meds**
  - Diphenhydramine 25 – 50 mg PO, IM (can worsen delirium)

- **Moderate: Consider IV/IM**
  - Haloperidol 0.5 mg – 2 mg PO, IV, IM
  - Olanzapine 2.5 mg – 5 mg Rapidly dissolving, PO, IM (do not co-administer IM olanzapine and benzodiazepine; following IM olanzapine, wait at least one hour and monitor for respiratory depression prior to use of benzo)
  - Lorazepam 0.5 – 2 mg PO, IV, IM

- **Severe: IV/IM**
  - Haloperidol +/- lorazepam +/- diphenhydramine

Pharmacological Interventions: Pregnancy Considerations

- Limit number of medications.
  - Give patients known medications first to limit exposures to fetus (ex. patient already receiving olanzapine).
  - Match IM/PO/IV medications.

- Anti-psychotics
  - Most data on haloperidol, olanzapine, and quetiapine during pregnancy. One-time doses are generally low risk and not associated with an increased risk in congenital malformations compared to general population (risk 2-3%) (1, 7).
  - 1st generation (haloperidol): less likely to have sedative or hypotensive effect compared to low potency anti-psychotic (4).
  - Less clear data on risperidone; recommend to generally avoid given other options available (unless patient already scheduled on this medication). Risperidone has higher relative infant dose and some studies show small increased risk of cardiac malformations (7).
  - If frequent administration of anti-psychotics in 3rd trimester, newborns should be monitored for theoretical risk of neonatal EPS. FDA warning (2011) about risk of exposure in 3rd trimester including neonatal EPS, sedation, breathing and feeding difficulties, increased/decreased muscle tone, agitation, tremor. These complications may resolve on their own or require additional hospitalization.

- Benzodiazepines
  - One-time doses may not have adverse effects; no study has assessed risk of outcomes after one time exposure, though data on long term treatment is reassuring (1).
  - Regular use early in pregnancy may be associated with spontaneous abortion.
  - One study showed possible association of benzodiazepines with congenital malformations with co-administration of SSRI; however, this study has not been replicated (13).
  - If frequent administration during third trimester, monitor newborns for floppy baby or neonatal withdrawal syndrome. Symptoms may include sedation, hypotonia, feeding difficulties.

- Contra-indicated: valproic acid (not generally used for acute agitation)

- Dosing: Medications metabolized by CYP P450 enzymes more rapidly metabolized during pregnancy and may require higher doses.
  - Examples: CYP3A4 – clonazepam/quetiapine; CYP2D6 – risperidone; Glucuronidation – lorazepam

*For more details about specific medications and effects during pregnancy, see table below.*
### Peripartum Agitation Medications

<table>
<thead>
<tr>
<th>Medication</th>
<th>Potential Indications</th>
<th>Maternal Acute Side Effects</th>
<th>Effects on Fetus/Birth in:</th>
<th>Starting Dose Ranges</th>
<th>Onset of Action</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Haloperidol (1st line if etiology of agitation unknown)</td>
<td>Mod/Severe Agitation</td>
<td>EPS (higher risk) Dystonia Sedation NMS Anti-cholinergic Effects QTc prolongation (worse with IV)</td>
<td>No evidence of increased congenital anomalies (evidence from retrospective study &gt; 100 pregnancy, prospective study &gt; 180 pregnancies, meta-analysis &gt;130,000 pregnancies)</td>
<td>Risk of neonatal EPS for ongoing use; no data of increased risk from one time use. FDA warning (updated 2011) for EPS, sedation, breathing/feeding difficulties, agitation, tremor, change in muscle tone; may resolve spontaneously or require additional hospital care.</td>
<td>PO: 0.5-1 mg TID PRN IV: 0.5 - 2 mg TID PRN IM: 5 mg once time Can increase to 4-20 mg/day NTE: 20 mg/day</td>
<td>PO: 45 – 60 mins IV &gt; IM: 15 – 30 mins</td>
</tr>
<tr>
<td>Olanzapine (alternative choice)</td>
<td>Mod/Severe Agitation</td>
<td>Sedation Orthostatic hypotension EPS Metabolic syndrome</td>
<td>No evidence of increased risk of congenital anomalies. Multiple studies/reviews showed rates of ectopic, premature or post-term birth, spontaneous abortion does not appear higher. Canadian study of 166 pregnancies showed no increased risk for gestational DM/HTN, preterm birth.</td>
<td>Risk of neonatal EPS for ongoing use; no data of increased risk from one time use. FDA warning (updated 2011) for EPS, sedation, breathing/feeding difficulties, agitation, tremor, change in muscle tone; may resolve spontaneously or require additional hospital care.</td>
<td>PO: 2.5 – 5 mg PO or IM BID PRN Can increase to 10-20 mg/day NTE: 20 – 30 mg/day</td>
<td>PO: 30 mins – 1 hour IM: 15 – 30 minutes</td>
</tr>
</tbody>
</table>
| **Quetiapine**  
(alternative choice) | **Primary psych**  
(mood stabilization) | **Sedation**  
Weight gain  
Metabolic syndrome  
Possible risk of increased gestational diabetes | **Not expected to increase risk of malformations (>5000 exposures, multiple case reports) based on limited data.** | **Risk of neonatal EPS for ongoing use; no data of increased risk from one time use** | **25 – 100 mg PO NTE: 300 mg daily for agitation** | **Lowest possible placental transfer (3.7%)** |
|---|---|---|---|---|---|---|
| Delirium  
Anxiety | | | | | | |

| **Lorazepam**  
(preferred benzo in pregnancy) | **Alcohol or Benzo withdrawal**  
Stimulant intoxication  
AMS 2/2 NMS, serotonin syndrome, catatonia  
Personality | **Sedation**  
Respiratory distress  
Memory Impairment  
Risk of falls/Incoordination  
Tolerance Dependence Withdrawal | **In general, does not appear to be associated with increased congenital anomalies.**  
**Data on congenital malformation association in one study with SSRI and benzos but has not been replicated.**  
**Increased risk of spontaneous abortions.** | **Exposure associated with “floppy baby” syndrome and neonatal withdrawal (requiring ICU admission); more likely from long term use** | **0.5 – 2 mg PO, IV, IM up to 2-3 times daily**  
**Increase as needed to 2-6 mg daily divided in doses**  
**NTE: 10 mg/day in divided doses** | **Black box warning: avoid use with opioids; abuse/misuse potential** |
| | | | | | | |
| | | | | | | |

| **Diphenhydramine** | **Mild agitation**  
Anxiety | **Sedation**  
Anticholinergic effects  
GI distress  
Impaired coordination | **Limited published data in pregnancy.**  
**Generally, not expected to increase risk of congenital abnormalities. There are some reports of associations with cardiac malformations (d-transposition great arteries) and cleft palate, though data is not consistent** | **One case report of neonatal withdrawal symptoms (irritability, sedation, tremulous, diarrhea).** | **25 – 50 mg PO, IV, or IM Q1-4 hours**  
**NTE: 300 mg/day** | **Dose dependent anticholinergic effect can make delirium worse** |
Peripartum Agitation References


Perinatal Anxiety

Deborah Cowley, MD
Perinatal Anxiety

Anxiety symptoms and/or positive screen (GAD-7 > 10)

Differential Diagnosis:
* Situational stress/Adjustment disorder (anxiety related to stressful life events, intimate partner violence/abuse, pregnancy-related anxiety)
* Anxiety secondary to medical condition (e.g., hyperthyroidism)
* Anxiety secondary to substance use/withdrawal, medications
* Primary anxiety disorder (meets DSM-5 diagnostic criteria for panic disorder, generalized anxiety disorder, social anxiety disorder, specific phobia)
* Anxiety secondary to another psychiatric disorder (if obsessions/compulsions, think of OCD; if trauma history, nightmares/flashbacks, think of PTSD)

Consider comorbidity: Depression common; many people with anxiety disorders have more than one!

Mild anxiety:
* Address stressors, provide information, problem-solving, increased social support
* Relaxation, mindfulness, meditation, yoga
* Consider psychotherapy

Moderate/severe anxiety:
* Psychotherapy (especially cognitive-behavioral therapy (CBT))
* Medication (weigh risks of untreated anxiety vs. risks of medications, alternative treatments)

Risks of untreated anxiety:
* Decreased placental blood flow
* Increased stress reactivity, HPA axis activation, cortisol levels
* Increased rates of preeclampsia, gestational hypertension, preterm birth, low birth weight, prolonged labor, postpartum hemorrhage
* Increased risk of postpartum depression; impaired attachment
* Cognitive and motor delays, emotional and behavioral problems in child

Risks of medications in pregnancy and lactation:
* SSRI antidepressants are first-line medication treatment for anxiety disorders
* No consistent increase in rates of malformations
* Persistent pulmonary hypertension of the newborn (PPHN; 2.9 vs. 1.8/1000)
* Neonatal adaptation syndrome in 30%; worse if also taking benzodiazepines
* Monitor breastfed infants for sedation/poor feeding
* Other medications can be used for adjunctive/as-needed treatment of anxiety (see Perinatal Anxiety Medications table for risks of benzodiazepines and other anxiolytics)

Alternative treatments:
* Psychotherapy (CBT)
* Mindfulness, meditation, relaxation
* Exercise, yoga

Goal:
* Treat to remission
* Track GAD-7 to measure progress/outcome
* If not improved, add medication/psychotherapy to existing treatment, try switching to another SSRI or an SNRI, and/or seek psychiatric consultation/referral
Perinatal Anxiety Medications

The first-line medication treatment for an anxiety disorder is an SSRI or venlafaxine. The anxiolytic medications below may be useful as adjunctive treatment, for occasional as-needed (PRN) use, or for patients who cannot tolerate or do not respond to first-line treatment.

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Starting Dose (mg)</th>
<th>Up titration/dosing schedule</th>
<th>Side effects</th>
<th>Use in Pregnancy</th>
<th>Use during Lactation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>BENZODIAZEPINES</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alprazolam®</td>
<td>0.25-0.5 TID</td>
<td>Increase weekly as needed; max 4 mg daily in divided doses</td>
<td>Benzodiazepine side effects include sedation, incoordination, memory impairment, tolerance, dependence, withdrawal; avoid use with opioids (black box warnings)</td>
<td>No increase in malformations&lt;sup&gt;c&lt;/sup&gt;</td>
<td>RID 3%; reports of infant sedation, withdrawal symptoms with weaning/discontinuation</td>
</tr>
<tr>
<td>Clonazepam®</td>
<td>0.25 BID</td>
<td>Increase in increments of 0.125-0.25 mg BID to 1-2 mg daily as needed</td>
<td></td>
<td>Increased rate of spontaneous abortion, preterm birth</td>
<td>Sedation, apnea reported in infants; monitor for sedation, poor feeding, poor weight gain</td>
</tr>
<tr>
<td>Diazepam®</td>
<td>2-5 BID</td>
<td>2-10 mg 2-4 times daily</td>
<td></td>
<td>Neonatal withdrawal, “floppy infant” syndrome; increase in NICU admissions</td>
<td>Sedation, weight loss reported in breastfed infants</td>
</tr>
<tr>
<td>Lorazepam®</td>
<td>0.5-1, 2-3 times daily</td>
<td>Increase as needed to 2-6 (max 10) mg daily in divided doses</td>
<td></td>
<td></td>
<td>Low levels in breast milk, no reports of sedation. Preferred benzodiazepine in lactation.</td>
</tr>
<tr>
<td><strong>OTHERS</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Buspirone®</td>
<td>7.5 BID</td>
<td>Increase by 5 mg every 2-3 days to 15 mg BID. After 3 weeks, increase further as needed; max 60 mg/day in divided doses</td>
<td>Dizziness, drowsiness, headache, nausea</td>
<td>Limited human data (75 reports of first trimester exposure, one infant with malformations); no inc in malformations in animals</td>
<td>Limited data (2 case reports); low levels in breast milk; seizures in one infant exposed to multiple medications</td>
</tr>
<tr>
<td>Gabapentin®</td>
<td>100, 1-3 times daily</td>
<td>Increase to 300-600 mg TID as needed</td>
<td>Dizziness, drowsiness</td>
<td>Possible inc in heart defects; inc in preterm birth, NICU admissions</td>
<td>Limited data; RID 1-4%; no adverse effects</td>
</tr>
<tr>
<td>Hydroxyzine®</td>
<td>25</td>
<td>Increase to 50-100 mg up to QID as needed</td>
<td>Drowsiness, dry mouth</td>
<td>240 exposures, no overall increase in malformations</td>
<td>Reports of infant sedation, irritability</td>
</tr>
<tr>
<td>Pregabalin®</td>
<td>25</td>
<td>Increase as needed to 150-600 mg daily in divided doses</td>
<td>Dizziness, drowsiness</td>
<td>&gt;3500 exposures; possible small increase in malformations</td>
<td>Limited data; RID 7-8%; one report of a breastfed infant with no adverse effects</td>
</tr>
<tr>
<td>Propranolol®</td>
<td>10</td>
<td>10 mg as needed, one hour prior to event</td>
<td>Contraindicated with asthma, bradycardia, hypotension, CHF</td>
<td>No inc malformations; ± IUGR; neonatal bradycardia, hypoglycemia</td>
<td>Low levels in milk; bradycardia, sedation in 2 infants exposed to multiple medications</td>
</tr>
<tr>
<td>Quetiapine®</td>
<td>25</td>
<td>Increase to 50-300 mg daily as needed</td>
<td></td>
<td>Sedation, weight gain, metabolic syndrome</td>
<td>Low levels in milk; RID&lt;1%; one infant with sedation</td>
</tr>
</tbody>
</table>

<sup>a</sup>Can be scheduled or prescribed PRN (as needed); buspirone is not effective as a PRN medication
<sup>b</sup>Dose for panic disorder can be 5-6 mg daily (max 10 mg daily) in divided doses
<sup>c</sup>Increased rate of spontaneous abortion, preterm birth
<sup>d</sup>Increase in malformations reported with benzodiazepine + SSRI exposure, but not with benzodiazepines alone

PERINATAL MENTAL HEALTH CARE GUIDE 26

PERINATAL PCL: (877) 725-4666

4/23/23
Perinatal Anxiety Resources

**Review article:**

**GAD-7 in other languages:**
The GAD-7 anxiety screening questionnaire is available in multiple languages at: [https://www.phqscreeners.com](https://www.phqscreeners.com)

**Patient manual:**

**Websites for patients:**
Calm
For meditation, dealing with stress, sleep
[https://www.calm.com/](https://www.calm.com/)

Headspace
For stress, anxiety, sleep, learning meditation
[https://www.headspace.com/](https://www.headspace.com/)
Assessing Safety

Cummings Rork, MD
Assessment of Safety Risk in Perinatal Populations

**Key Facts:**
- Suicide is the leading cause of direct death within first year of postpartum period (8% in WA)
- Suicide is more likely to occur in the postpartum period (and more likely after 6-week postpartum visit)
- Postpartum women with a history of depression are at a 70% increased risk for death by suicide
- Women diagnosed with a postpartum mental disorder are 6.2x higher risk for self-harm compared to mothers without mental disorders
- Pregnant women with alcohol abuse are 3.7x more likely to feel suicidal compared to those without alcohol abuse
- In pregnancy-associated suicides, 54.3% of victims experienced problems with a current or former intimate partner that appeared to have contributed to the suicide
- For patients with untreated postpartum psychosis, 5% die by suicide

**Warning Signs:**
- Sadness
- Withdrawn
- Change in sleep or eating habits (esp. severe insomnia)
- Loss of pleasure of activities that normally bring joy
- Giving away possessions
- Helplessness
- Feelings of worthlessness
- Anger, seeking revenge
- Significant estrangement from infant
- Feeling trapped
- Overwhelming anxiety, panic, or agitation
- Alcohol or drug use increase
- Change in personality, emotional lability
- Strong feelings of guilt or shame
- Recklessness or impulsivity
- Purposelessness (feeling like a burden, family would be better without them)
- Psychosis

**CRITICAL SIGNS**
- Hopelessness
- Talking about death
- Seeking methods for self-harm (searching online, obtaining a gun*)

*Women who die by suicide during the postpartum period use violent and lethal means more frequently than non-perinatal women

Depression Screen: PHQ-9 → 1+ score for Question 9

Complete Columbia-Suicide Severity Rating Scale (C-SSRS) or Ask Suicide-Screening Questions (ASQ) to determine level of risk
### Assessment of Safety Risk in Perinatal Populations (Cont.)

<table>
<thead>
<tr>
<th>Protective Factors</th>
<th>Risk Factors</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Positive &amp; available social support</td>
<td><strong>Predisposing Historical factors:</strong></td>
</tr>
<tr>
<td>• Cohabitation with partner</td>
<td>• Personal hx of suicidal ideation/behavior</td>
</tr>
<tr>
<td>• Positive therapeutic relationship</td>
<td>• Hx of mental disorder</td>
</tr>
<tr>
<td>• Responsibility to others (family, children)</td>
<td>• Hx of substance use disorder &amp; cannabis use</td>
</tr>
<tr>
<td>• Fear of death</td>
<td>• Lifetime hx of rape, or hx of childhood abuse</td>
</tr>
<tr>
<td>• Positive problem-solving or coping skills</td>
<td>• Medical illness (e.g. HIV+ status)</td>
</tr>
<tr>
<td>• Hope for future, future-oriented</td>
<td>• Death of family member by suicide</td>
</tr>
<tr>
<td>• Intact reality testing</td>
<td>• Younger age</td>
</tr>
<tr>
<td>• Fear of social disapproval</td>
<td>• Traditionally marginalized and underserved populations (e.g., LGBTQAI+, Black, Native American/Alaskan Native)</td>
</tr>
<tr>
<td>• Religious beliefs against suicide</td>
<td>• Veteran</td>
</tr>
<tr>
<td>• Life satisfaction</td>
<td>• Physician</td>
</tr>
</tbody>
</table>

**Situation factors:**
- Unintended/unwanted pregnancy
- Obstetrical/neonatal complication
- Loss (e.g., pregnancy loss)
- Recent discharge from inpatient psychiatric unit
- Family or marital conflict
- Social withdrawal/isolation
- Unmarried
- Recent IPV
- Unemployment/financial instability
- Medical problems
- Legal issues
- Community factors (i.e., war, discrimination)
- Health systems factors (i.e., barriers to access, stigma)

*Other factors:* Depressive symptoms (SIGECAPS), feeling estranged/distant from child, psychosis, or suicide warning signs

### Health Consequences of Nonfatal Suicide Attempt

<table>
<thead>
<tr>
<th>Obstetric Health</th>
<th>Impact on Children</th>
</tr>
</thead>
<tbody>
<tr>
<td>Increased risk of:</td>
<td>• Fetal death</td>
</tr>
<tr>
<td>• Antepartum hemorrhage</td>
<td>• Neurodevelopmental abnormalities</td>
</tr>
<tr>
<td>• Placental abruption</td>
<td>• Low birth weight</td>
</tr>
<tr>
<td>• Postpartum hemorrhage</td>
<td>• Stillbirth</td>
</tr>
<tr>
<td>• Premature delivery</td>
<td>• Poor fetal growth</td>
</tr>
<tr>
<td></td>
<td>• Fetal abnormalities</td>
</tr>
</tbody>
</table>

**Safety Planning:**
- Foster a sense of connectedness (e.g., hope, connect with family)
- Initiate or refer to specialty care
- Assess for firearms, medications, and other lethal means. Work to secure any lethal means.
- Collaborate in creating safety plan. See [Stanley-Brown](#) below for example.
- Discuss Reasons for Living
## Assessment of Safety Risk in Perinatal Populations (Cont.)

<table>
<thead>
<tr>
<th>Low Risk (SI without plan or intent)</th>
<th>Moderate Risk (SI with plan, no intent; previous SA)</th>
<th>High Risk (SI with plan and intent)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Establish/maintain therapeutic alliance</td>
<td></td>
<td>Close follow-up once emergent management by psychiatry established</td>
</tr>
<tr>
<td>Regular follow-up with repeated risk assessment</td>
<td>Closer follow-up with repeated risk assessment</td>
<td></td>
</tr>
<tr>
<td>Referral to psychiatry</td>
<td>Urgent referral to psychiatry</td>
<td>Emergency psychiatry consultation in ER; may need psychiatric hospitalization (mother-baby unit)</td>
</tr>
<tr>
<td>Initiate treatment (consider pharmacotherapy)</td>
<td>Initiate treatment, including pharmacotherapy</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Optimize social support</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Psychoeducation</td>
<td></td>
</tr>
</tbody>
</table>
Resources for Assessing Safety

For Providers:

Stanley-Brown Patient Safety Plan Template:

ASQ Suicide Risk Screening Tool:
https://www.nimh.nih.gov/research/research-conducted-at-nimh/asq-toolkit-materials/

Safety Planning Training Videos:
https://suicidesafetyplan.com/training/

Patient Resources:

Perinatal Support Washington Warm Line:
- 1-888-404-7763
- https://perinatalsupport.org

Washington State Crisis Line Access:
- 9-8-8 (7-1-1 for TTY)

King County Crisis Line:
- 866-4-CRISIS

National Suicide Prevention Lifeline:
- 9-8-8 (1-800-273-8255)
- Crisis support via text message: Text HOME to 741741
- Crisis support via chat: www.suicidepreventionlifeline.org

Washington Warm Line:
- 1-877-500-9276

Washington Recovery Help Line:
- 1-866-789-1511
Resources for Assessing Safety (Cont.)

**Survivors of Suicide Support Groups:**

*For families/patients:*

American Foundation for Suicide Prevention Directory:  
[https://afsp.org/find-a-support-group/](https://afsp.org/find-a-support-group/)

WA DOH Suicide Grief Support Resources:  

Crisis Line Support Group Directory:  

2020 Mom Remembrance Wall:  
[https://www.2020mom.org/remembrance-wall](https://www.2020mom.org/remembrance-wall)

*For clinicians:*

Coalition of Clinician Survivors  
[www.cliniciansurvivor.org](http://www.cliniciansurvivor.org)
Intimate Partner Violence Risk Assessment

**Definition:** The term “intimate partner violence” describes a single or repeated act of physical violence, sexual violence, stalking, psychological harm, or control of reproductive health perpetrated by a current or former partner or spouse. “Intimate partner” refers to an individual with whom one has a close personal relationship (i.e., spouse, former partner, family member).

**Be vigilant:**
- Violence against women have increased to unprecedented levels since the pandemic
- Technology-facilitated abuse is a significant, harmful phenomenon and emerging trend in IPV
- IPV (esp., physical abuse) is associated with suicidal ideation and deaths (high frequency = increased risk)
- ~3-8% prevalence of perinatal IPV, likely higher in LGBTQIA community
- Pregnancy is the 2nd most dangerous time in a violent relationship, and is a risk factor for dying by homicide
- Homicide is the leading cause of death in pregnancy and in postpartum (9% in WA)
- Homicide pregnancy-associated death ratio increased 63% in the past decade (1.8 → 3.0 per 100,000 births); rates are highest during pregnancy (56.8%) or after 6-weeks postpartum (34.9%); people who identify as non-Hispanic Black or younger age (15-24) are at highest risk of homicide
- BIPOC people suffer the impact of IPV and intimate partner homicide disproportionately
- Intersecting identities can exacerbate the experience and impact of IPV, as individuals may face multiple forms of oppression and marginalization that can increase their vulnerability to violence and limit their access to resources and support.

**Risk Factors for IPV:**
- Prior IPV (which raises the risk of violence during pregnancy as much as 14 times)
- Young age, particularly adolescents
- Individuals who are single, unmarried, or who are living apart
- Fewer years of education (particularly if less than a high school education)
- Co-existing medical or obstetric complication
- Being publicly insured or on Medicaid
- Unplanned/Mistimed pregnancy or ambivalence about the pregnancy

**Additional Risk Factors for IPV**
- Access to gun and/or prior use of weapon
- Suicidal and/or homicidal threats (partner, children, pets)
- Partner with SUD
- Strangulation
- Hostage-taking
- Escalation of IPV
- Forced sexual activity
- Possessiveness/jealousy
- Stalking behavior

**Warning Signs/Indicators of IPV:**
- Poor attendance/nonattendance to clinic visits
- Repeat visits for minor injuries or concerns
- Nonadherence to care plan
- Repeat presentation with depression, anxiety, self-harm, or other psychosomatic symptoms
- Physical injuries that are untended and located in several locations of varying degrees of age, especially to neck, head, breasts, abdomen, and genitals
- Past poor obstetric outcomes (repeated miscarriage, stillbirths, preterm labor/birth, IUGR or low birth weight)
- Partner demanding to be included in visit or domineering during visit
- Sexually transmitted infections or frequent UTIs, vaginal infections, or pelvic pain
- Minimalization of physical injuries
Consequences of IPV

**Mental Health:**
- PTSD
- Anxiety
- Major Depressive Disorder
- Eating Disorders
- Suicide
- Substance Use Disorders

**Obstetric Health:**
- No or delayed prenatal care
- High blood pressure, edema
- Vaginal bleeding in 2nd or 3rd trimester
- Severe nausea, vomiting, or dehydration
- Kidney infection or UTI
- Premature rupture of membranes, premature birth
- Placental abruption
- Miscarriages
- Preterm birth
- Diminished intrauterine growth
- Homicide
- Death of fetus
- Stillbirth

**Impact on Children:**
- Less likely to be breastfed
- Failure-to-thrive
- Death
- Increased risk for mental illness
- Sleep disturbances
- Higher irritability
- Deficits in executive functioning
- Deficits in cognitive functioning
- Delays in achieving developmental milestones
- Insecure or disorganized attachment
- Increased risk for additional adverse childhood events including child abuse
- Increased risk for both using and experiencing IPV as an adult

**Psychosocial Impact:**
- Housing instability & homelessness
- Unemployment
- Loss or delay in educational opportunities
- Food insecurity
- Financial instability
- Unwanted entanglement in legal systems

**PEARLSS for Trauma-informed Care:**
- P - Partnership: Collaborate and empower the survivor, respecting their autonomy.
- E - Empathy: Validate experiences without judgment, demonstrating understanding.
- R - Respect: Honor dignity, choices, and boundaries, promoting nonviolence.
- L - Listen and Learn: Create a safe space for sharing, continuously learn about trauma.
- S - Strengths-Based Approach: Focus on strengths, resilience, and coping mechanisms.
- S - Safety: Prioritize physical and emotional safety, fostering trust and empowerment.
Intimate Partner Violence Risk Assessment (Cont.)

Considerations with Screening

If your patient says “YES,” ask:
1. Are you safe now?
2. Would you like to talk about it?
3. When did this happen?
4. Have you talked with anyone else about this?
5. How are you coping?
6. What do you need right now?

- IPV screening is recommended for all women of childbearing age
  - Screen at least 1x/trimester and at postpartum visits
  - Other times: intakes, annually, new intimate relationship, when suspected
    - Think about including information in discrete areas in the clinic (i.e., restrooms/stall doors)
- Do not screen if another adult or child > 2 y/o is present
- Review the limits of confidentiality with the patient beforehand
- Be mindful of how you screen (self-report vs clinician-led questionnaire, before visit/in lobby, in office, survey that includes all types of violence, culturally adapted, gender-neutral, non-heteronormative)
- Ask behaviorally specific questions to yield more accurate responses (i.e., “Has your partner ever strangled you?” instead of “Has your partner ever abused you?”)
- Assess immediate safety and other health concerns/needs
- Offer choices (referrals, list of local resources e.g., crisis lines, shelter)
- Respect and recognize the patient’s autonomy in decision-making

Considerations with Documentation

- Be mindful of how to document your conversation and collaborate with the patient in your response
- Be aware of who may have access to the medical record
- Use recovery-oriented, non-stigmatizing terms (i.e., someone who uses/experiences violence, not victim/perpetrator)

Sufficient, Detailed, and Accurate

- Include date(s) and description of event(s), use the patient’s words verbatim with quotations, and document detailed information of objective physical signs and behaviors (consider anatomical diagrams, photos)
- Collect and document information about the individual who used violence (name, address, relationship to patient, etc.)
- Other considerations: (in)consistency between subjective and objective findings, children in home, pregnancy status of patient, etc.

Safety Planning

Safety is priority. Depending on what the individual wants to do, safety planning may include safety within the relationship, safety while leaving the relationship, and safety after leaving the relationship. Please visit “More Resources for Providers” for some safety planning forms (and attached at end of this guide).
### Intimate Partner Violence Risk Assessment (Cont.)

<table>
<thead>
<tr>
<th>How to Stay Safe Within the Relationship</th>
<th>How to Safely Leave the Relationship</th>
<th>How to Stay Safe After Leaving the Relationship</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Identifying safe areas of the home</td>
<td>- Contacting a local domestic violence shelter or national hotline</td>
<td>- Filing for a restraining order or order of protection</td>
</tr>
<tr>
<td>- Gathering important documents such as copies of birth certificates</td>
<td>- Documenting any injuries (clinician can do this during the visit and place pictures in the medical record)</td>
<td>- Changing the route to work and/or school</td>
</tr>
<tr>
<td>- Making copies of important financial or ownership documents</td>
<td>- Identifying a safe place to stay</td>
<td>- Changing the locks</td>
</tr>
<tr>
<td>- Providing assistance with contraceptive health and screening for sexual health issues</td>
<td></td>
<td>- Alerting neighbors, family, co-workers, or school personnel to call the police if they see the individual</td>
</tr>
<tr>
<td>- Practicing how to escape if needed and have an escape bag packed</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Resources for Intimate Partner Violence

Screeners

Abuse Assessment Screen

Woman Abuse Screening Tool

Danger Assessment Screening
https://www.dangerassessment.org/DA.aspx

Additional Resources

Domestic Violence Personalized Safety Plan
  o https://www.thehotline.org/plan-for-safety/create-your-personal-safety-plan

National Domestic Violence Hotline
  o 1-800-799-SAFE (Voice) | Free. Confidential. 24/7.
  o 1-800-787-3224 (TTY) | Free. Confidential. 24/7.

National Teen Dating Violence Hotline, online chat, and texting
  o https://www.loveisrespect.org

National Sexual Assault Hotline
  o 1-800-56-HOPE (4673) | Free. Confidential. 24/7.
  o https://rainn.org/get-help/national-sexual-assault-hotline/

Database of Domestic Violence Programs and Shelters
  o www.domesticshelters.org

Washington Department of Health Resources

Database of Sexual Assault and Domestic Violence Services in Washington
  o Locate sexual assault service providers in WA: http://www.wcsap.org/find-help
  o Locate domestic violence service providers in WA: http://wscadv.org/washington-domestic-violence-programs/
Intimate Partner Violence Resources (Cont.)

Resources for Clinicians

Vicarious trauma is real, and self-care and support are important:

- Seek professional support: Supervision, consultation, and peer support.
- Education and training: Attend workshops on self-care and trauma-informed care.
- Practice self-care: Mindfulness, exercise, boundaries, and enjoyable activities.
- Access supportive resources: Read books/articles and use online mental health resources.
Assessment of Risk for Harm of Infants and Children

**Key Facts:**
- Infants are at risk for homicide more than any other age group
- The highest risk for infant homicide is during first 24 hrs of life
- Homicide is the second leading cause of injury-related death for children <1 year
- Forms of child maltreatment preceding infant death are neglect (72%) & physical abuse (44%)
- In WA state, 25% of children entering foster care are infants under 1 year, the second highest rate in the country
- For patients with untreated postpartum psychosis, 4% commit infanticide
- Aggressive or infanticidal ideation in women with depression or facing stress is common (26-43% incidence)
- 16-29% of filicides occur in the context of maternal suicide
- ~74% of infant/child homicides were weapon-related deaths
- Early childhood experiences have lasting impacts on well-being, and timely interventions aid in healing for maltreated babies and families.

**Maternal Characteristics**
- Denial of pregnancy
- Late initiation of pregnancy care
- Depression
- Psychosis (delusions of threat to safety, auditory/command hallucinations)
- Suicidality
- Significant life stress
- Low SES
- Young age
- Unmarried
- Lower educational achievement
- Socially isolated
- IPV
- Family history of violence
- History or current child abuse/neglect
- Full-time caregiver/unemployment
- Persistent crying or other child factors (e.g., colic, autism)
- Child custody dispute
- Thoughts of revenge against spouse

**Infant Characteristics:**
- 1-day old
- Low gestational age
- Low birthweight
- Low Apgar score
- Male sex
- And/or Non-Hispanic Black race

**Definitions:**
- **Neonaticide**: the killing of an infant during first 24 hrs of life
- **Infanticide**: the killing of an infant (age 1 day old to 1 year old)
- **Filicide**: the killing of a child (age ≥1)

**Other risk factors:**
- Access to firearms
- Exposure to domestic violence
- Exposure to substance use

**Know the signs:**
- Physical signs of neglect (poor hygiene, dental caries, poor weight gain or weight loss, severe diaper dermatitis, and unattended medical needs)
- Unexplained injuries (bruises, burns, fractures, or head injuries)
- Extreme behaviors (excessive crying, truancy, running away, or aggression)
- Delay in seeking care, missing or inconsistent medical history, or inconsistent explanations for injuries
- Signs of emotional abuse (low self-esteem, depression, anxiety, or withdrawal)
- Signs of sexual abuse (difficulty walking or sitting, pain or itching in the genital area, or inappropriate sexual behavior or knowledge)
- Signs of neglect (lack of supervision, regular signs of hunger, inappropriate dress, poor hygiene, distended stomach, or emaciation)
**Common Motives:**

1. **Altruistic:** death of child out of love or belief this is in the best interest of the child; often planned or considered for some time
2. **Acutely psychotic:** no comprehensive motive (e.g., command auditory hallucinations); tends to be impulsive
3. **Fatal maltreatment:** death is not anticipated outcome, a result of abuse, neglect, or fabricated/induced illness or injury by caregivers (i.e., Munchausen by proxy syndrome)
4. **Unwanted child:** mother perceives child as burden
5. **Spouse revenge:** child is killed to specifically cause emotional harm to spouse; rare
6. **Cultural:** death of the child due to cultural beliefs or practices; rare

**Sample Questions:**

- Do you have any concerns about the safety of your child(ren)?
- Are you having any thoughts or fears of harming other people?
- Are you having any thoughts or fears of harming your child(ren)?
- Are there other people (or children) you want to die with you?
- Are there others you think would be unable to go on without you?
- What will happen to your child(ren) if you die?

**Important Consideration:**

Fear of removal of children from home is real and common. This may lead to concern about disclosure or minimization of symptoms or risky behaviors (e.g., substance use). If after risk assessment, referral for protective services is determined to be necessary, extra vigilance and care are required. Disruption of therapeutic alliance may occur, leading to avoidance of care or treatment, and potentially increase risk for maternal mental health disorder or suicide.
Resources for Assessment of Risk for Harm of Infants and Children

**General Resources:**

- Child Protective Services

- Zero to Three Safe Babies Program
  [https://www.zerotothree.org/our-work/safebabies/](https://www.zerotothree.org/our-work/safebabies/)

- Child Help Hotline: 1-800-4-A-CHIL (1-800-422-4453)
  [https://www.childhelp.org/educator-resources/child-abuse-education-prevention-resources/](https://www.childhelp.org/educator-resources/child-abuse-education-prevention-resources/)

- The Period of Purple Crying

- Help Me Grow WA
  1-800-322-2588
  [http://www.parenthelp123.org/resources/family-health-hotline/](http://www.parenthelp123.org/resources/family-health-hotline/)

- WA Warm Line
  1-877-500-9276

- WA Recovery Help Line
  1-866-789-1511

- Teen Link (ages 13-20)
  1-866-833-6546

- WA State Crisis Line Access
  7-1-1

- King County Crisis Line
  866-4-CRISIS

- National Suicide Prevention Lifeline
  1-800-273-8255, 9-8-8
  Crisis support via text message: Text HOME to 741741
  Crisis support via Chat: [suicidepreventionlifeline.org](http://suicidepreventionlifeline.org)

- Perinatal Support Washington
  1-888-404-7763
  [https://perinatalesupport.org](https://perinatalesupport.org)
For Providers:

**Articles:**
Prevention of Infanticide and Suicide in the Postpartum Period—the Importance of Emergency Care
[https://jamanetwork.com/journals/jamapsychiatry/article-abstract/2738767](https://jamanetwork.com/journals/jamapsychiatry/article-abstract/2738767)

Child Murder by Mothers
[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2174580/](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2174580/)

**Books:**
Infanticide Psychosocial and Legal Perspectives on Mothers Who Kill
[https://www.appi.org/Products/Trauma-Violence-and-PTSD/Infanticide](https://www.appi.org/Products/Trauma-Violence-and-PTSD/Infanticide)

**References:**


Perinatal Bipolar Disorder

Amritha Bhat, MD
Perinatal Bipolar Disorder

Key facts: 60–70% of women with bipolar disorder (BD) experience a mood episode during pregnancy and the postpartum period. Screen for BD in all individuals with perinatal depression, especially if you are considering starting an antidepressant. For those who screen positive, prioritize safety assessment and management of sleep disturbance while awaiting psychiatric evaluation.

Diagnostic criteria for bipolar disorder:
Bipolar I disorder: at least one lifetime manic or mixed episode; Bipolar II disorder: at least one lifetime hypomanic episode and at least one episode of major depression.
Symptoms of mania (lasts 1 week or requires hospitalization): D = Distractibility, I = Irresponsibility, G = Grandiosity, F = Flight of ideas, A = Activity increase, S = Sleep deficit, T = Talkativeness. Symptoms of hypomania – same as mania, for 4 days / without impairment

Screening tools:
CIDI (Composite International Diagnostic Interview) based screening tool for bipolar spectrum disorders – 3 minutes to complete, clinician administered.
MDQ (Mood Disorder Questionnaire) – 5 minutes to complete, self-report.
Critical to screen for comorbidities such as anxiety, substance use

Pharmacological treatments:
Use monotherapy where possible
Individual risk benefit analysis is important
Acute treatment of perinatal bipolar depression: lamotrigine or quetiapine
Acute treatment of mania or mixed: quetiapine, benzodiazepine, lithium
Maintenance: Lamotrigine, lithium, second generation antipsychotic

Non-pharmacological interventions:
Cognitive Behavior Therapy (CBT)
CBT – Insomnia
Interpersonal and Social Rhythm Therapy
Light therapy
Counsel on lifestyle issues and sleep, help plan how to implement these suggestions

A note on postpartum psychosis:
Also see Postpartum Psychosis (Page 65)
Rare (prevalence 0.1%) but a psychiatric emergency requiring hospitalization.
Rapid onset, highest risk in first 4 weeks postpartum, may occur up to 12 weeks postpartum
Higher risk in those with past episodes and bipolar disorder
Symptoms: mood swings, confusion, strange beliefs and hallucinations

Effects of untreated bipolar disorder:
On mother: Risk of relapse, suicide, comorbidities
Antepartum hemorrhage, placental abnormalities

On baby: preterm birth, low birth weight, microcephaly, neonatal hypoglycemia

Relapse of BD during pregnancy increases risk of postpartum episodes 3 to 7 fold

Risk assessment:
Also see Assessing Safety (Page 27)
Suicide risk: C-SSRS or NIMH ASQ
Risk of infant harm – First determine if thought of harming infant is an intrusive thought (unwanted negative thoughts that are frequent and difficult to dismiss) or infanticidal ideation (due to a psychotic symptom). Ask questions assessing specific content of the thought, and emotional and behavioral responses to thoughts.
Examples of other questions that could be asked, taken from the Postpartum Bonding Questionnaire (Brockington et al 2006)
• Have you felt irritated by your baby?
• Have you had significant regrets about having this baby?
• Does the baby feel like it’s not yours at times?
• Have you wanted to shake or slap your baby?
• Have you ever harmed your baby?
## Perinatal Bipolar Disorder Medications

(See Page 67 for **Information on Antipsychotics**)

<table>
<thead>
<tr>
<th>Drug Name (Common brand name)</th>
<th>Starting Dose and titration</th>
<th>Common side effects / adverse effects</th>
<th>Use in Pregnancy</th>
<th>Use during Lactation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lamotrigine (Lamictal)</td>
<td>25 mg / day for 2 weeks: 50 mg / day for 2 weeks; 100 mg for 1 week, 200 mg (usual maximum dose)</td>
<td>Serious rash including Stevens Johnson syndrome, nausea, dizziness, ataxia</td>
<td>No increased risk of congenital malformations 29% need dose increase during pregnancy. If dose was increased during pregnancy, taper by 25% immediately post-birth and gradually back to baseline within two weeks postpartum.</td>
<td>RID 1.8 – 21. Considered compatible. Monitor for sedation / rash in infant.</td>
</tr>
<tr>
<td>Lithium</td>
<td>Acute mania/mixed episodes / or acute bipolar major depression: Initial: 600 to 900 mg/day in 2 to 3 divided doses; increase based on response and tolerability by 300 to 600 mg every 1 - 5 days to usual therapeutic dose range of 900 mg/day to 1.8 g/day. ¹</td>
<td>Hypothyroidism, polyuria, weight gain, serotonin syndrome</td>
<td>Ebstein's anomaly² – rate of 0.01 – 0.05% compared to a population risk of 0.005% Higher odds of: Any congenital anomaly (4.1%, OR 1.8, NNH 33) Cardiac anomaly (1.2%, OR 1.86, NNH 71) Increased rates of neonatal readmission No known effects on neurodevelopment Check levels monthly through 34 weeks then weekly. May need increased dose. Adequate hydration during labor, decrease dose to pre pregnancy dose after delivery.</td>
<td>RID 3 – 69. Not considered compatible.</td>
</tr>
<tr>
<td>Valproate (Depakote)</td>
<td>Not considered safe to start during pregnancy / in reproductive age people in general</td>
<td>Dry mouth, tremors, headache, weight gain</td>
<td>Dose dependent increased rate of congenital malformations – 5 to 25% (neural tube³ cardiac and craniofacial) and neurodevelopmental problems (reduced IQ, autism spectrum disorders, and attention-deficit/hyperactivity disorder)</td>
<td>RID 0.1 – 3.9. Considered relatively safe, but not considered safe in people of reproductive potential. Monitor infant for sedation</td>
</tr>
<tr>
<td>Carbamazapine (Tegretol)</td>
<td>Not considered safe to start during pregnancy / in reproductive age people in general</td>
<td>Dizziness, ataxia, blurred vision, nausea, rash</td>
<td>Dose dependent increased rate of congenital malformations 3 to 9% (neural tube³, urinary tract and craniofacial malformations).</td>
<td>RID 1.1 – 7.3. Considered relatively safe. Monitor infant for sedation</td>
</tr>
<tr>
<td>Oxcarbazepine</td>
<td>Not safe to start during pregnancy / in reproductive age people in general</td>
<td>Dizziness, ataxia, blurred vision, nausea, rash</td>
<td>Insufficient information but appears to be less frequently associated with congenital malformations.</td>
<td>RID 1.5 – 1.7. Considered relatively safe. Monitor infant for sedation.</td>
</tr>
</tbody>
</table>

RID= relative infant dose; NNH = number needed to harm

1. Check serum levels - 0.8 and 1.2 mEq/L recommended; some respond to lower levels (eg, 0.6 mEq/L).
2. Displacement of the tricuspid valve into the right ventricle; prognosis depends on severity of the lesion. Obtain high resolution ultrasound and fetal echocardiogram at 16 weeks gestation.
3. Risk of neural tube defects may be reduced if folic acid 5 mg is taken for one month preconception and throughout first trimester. Obtain high resolution morphological ultrasound with assessment of nuchal translucency.

PERINATAL PCL: (877) 725-4666
Perinatal Bipolar Disorder Resources and References

**Resources**

**Review article:**
Review of psychotropic drug use for bipolar disorder in the perinatal period:

**Patient handouts:**
Handout from the International Society of Bipolar Disorders on healthy routines and rhythms during the pandemic and beyond:
https://www.isbd.org/Files/Admin/COVID_PSA/COVID_PSA_English.pdf

Wellness tracker from Depression and Bipolar Support Alliance that includes mood, medication and lifestyle trackers:
https://www.dbsalliance.org/wellness/wellness-toolbox/wellness-tracker/

**References**


Perinatal Cannabis Use

Jessie Goodman, MD
Perinatal Cannabis Use

What is cannabis?

- Cannabis is the most commonly used drug during pregnancy. Rates vary widely from 2-8% of pregnant patients, but higher in those age 18-25 yo (up to 15%). Prevalence of use in pregnancy is increasing, and potency of cannabis is increasing.

- Cannabis is a plant that contains more than 80 biologically active chemical compounds. The most commonly known compounds are delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD).

Perinatal cannabis use

- 30-60% of regular users continue during pregnancy

- Many pregnant patients have strong beliefs about using cannabis and associate its use as inherently safe.

- If providers do not raise the subject of use, many patients assume that it means there is no or low risk.

- Patients may hear conflicting advice regarding safety and use; keep the conversation open and engage in reflective listening

- ACOG, AAP, FDA, CDC, ABM all advise to avoid cannabis use in pregnancy and lactation

Risks of cannabis use in pregnancy: *

<table>
<thead>
<tr>
<th>Perinatal Complication Risks</th>
<th>Developmental Outcome Risks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fetal growth restriction</td>
<td>Disruption in brain development</td>
</tr>
<tr>
<td>Low birth weight</td>
<td>Reduction in verbal &amp; visual reasoning</td>
</tr>
<tr>
<td>Small for gestational age</td>
<td>Memory and attention deficits</td>
</tr>
<tr>
<td>Risk for stillbirth</td>
<td>Executive function deficits</td>
</tr>
<tr>
<td>Higher NICU admission rate</td>
<td>Increased risk for psychopathology</td>
</tr>
<tr>
<td>Neonatal withdrawal symptoms</td>
<td></td>
</tr>
</tbody>
</table>

*Studies are not always well controlled and have limitations. Risks may be dose dependent.
Perinatal Cannabis Use (Cont.)

Screen all patients for substance use during pregnancy with NIDA quick screen or 4Ps. Recurrent screening should occur with ongoing or new concerns for substance use during pregnancy. Some pregnant people may choose to avoid substances during pregnancy but resume use after delivery, therefore screening must be repeated during the postpartum period.

(See Substance use in pregnancy guide for further information)


Ensure all patients are asked: Have you ever used cannabis?

<table>
<thead>
<tr>
<th>If a patient endorses cannabis use:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ask open ended questions using non-judgmental language. Use a harm reduction, trauma-informed, and culturally informed approach that is person-centered</td>
</tr>
<tr>
<td>- How often are you using and how much at a time?</td>
</tr>
<tr>
<td>- How do you use (edibles, smoking, vaping, dabbing, topical)?</td>
</tr>
<tr>
<td>- Are you using for recreation or to treat a condition such as:</td>
</tr>
<tr>
<td>- nausea, pain, to improve appetite, anxiety, depression, managing withdrawal from other substances</td>
</tr>
<tr>
<td>(Acknowledge these are medical conditions that require treatment and support, and explore treating the underlying condition with a more evidence-based alternative)</td>
</tr>
<tr>
<td>- Does your partner or other household members use?</td>
</tr>
<tr>
<td>- Are you interested in decreasing/stopping use or have you tried in the past? If Yes, see substance use disorders guide in pregnancy for resources and motivational interviewing techniques</td>
</tr>
<tr>
<td>- What have you already discussed with other providers?</td>
</tr>
</tbody>
</table>

Assess for possible cannabis use disorder (see below)

Cannabis use disorder (CUD)

Up to 18% of pregnant patients using cannabis meet criteria for CUD

Screen using the CUDIT-R

For referral to treatment, see Resource Guide: https://perc.psychiatry.uw.edu/care-guide

Screen and treat for co-morbid disorders (including mood disorders, insomnia, nausea)

Medication treatment: no currently approved medications. Some limited evidence for gabapentin and N-acetylcysteine (NAC)

NAC: no evidence regarding risk for use in pregnancy

Gabapentin: limited data, possible increased risk of cardiac malformations, risk for pre-term birth, SGA, and NICU admission (particularly in late pregnancy). Limited data on use during lactation
Perinatal Cannabis Use (Cont.)

**Cannabis and lactation:**

Regardless of method of use, the active ingredients of cannabis pass into breast/chest milk.

- Babies are estimated to ingest 0.4%-8.7% of parental dose via milk
- **Discarding pumped milk does not eliminate risk of THC in milk.** THC remains in fatty tissue from 6 days to greater than 6 weeks, even after discontinuing use.

There are limited quality long-term studies on the safety of cannabis exposure via human milk.

**Potential risks:**

- adverse effects on neurodevelopment, including delayed motor development
- possible delayed growth

**CBD (non-psychoactive cannabis component)**

Used for pain, anxiety, insomnia, depression, PTSD, headaches, nausea, seizures disorders and many more conditions (studies are ongoing regarding outcomes and side effects in non-pregnant adults)

Scarce research of pure CBD use during pregnancy and lactation. Research is not conclusive as to safety or harm.

**Possible risks in pregnancy:**

- Animal research finds disruption in reproductive system of male fetuses
- Human tissue studies find decreased angiogenesis in umbilical cells, that may lead to pregnancy complications (placental insufficiency/pre-eclampsia) and dysregulation in the fetal immune system

If long term use, and experiencing N/V, consider cannabinoid hyperemesis syndrome:

**Cannabinoid Hyperemesis Syndrome (CHS)**

- Rare disorder with repeated regular use for at least one year
- Symptoms can include repeated episodes of nausea and /or vomiting, belly pain, diarrhea
- Consider in pregnant patients with long term cannabis use with pre-pregnancy nausea symptoms
- Main treatment: to discontinue cannabis use. See cannabis use disorder above.
Perinatal Cannabis Use Resources

Resources:

SAMHSA Cannabis in Pregnancy Evidence Based Resource Guide:

ACOG Cannabis Committee Opinion:

Perinatal Services BC Cannabis Guide for providers:

Cannabis and Washington State Law:

For patients:

Mother To Baby Cannabis Fact Sheet:
https://mothertobaby.org/fact-sheets/marijuana-pregnancy/

MGH Center for Women’s Health: Cannabis Use and Brain Development

MGH Center for Women’s Health: Cannabis Use and Breastfeeding
https://womensmentalhealth.org/posts/cannabis-and-breastfeeding/
Perinatal Depression

Deborah Cowley, MD
# Perinatal Depression

**Common:** 12-15% in pregnancy, 22% postpartum, in 5-10% of non-gestational parents, more common and lower rates of screening and treatment in BIPOC individuals

<table>
<thead>
<tr>
<th>Screening:</th>
<th>Differential Diagnosis:</th>
</tr>
</thead>
<tbody>
<tr>
<td>PHQ-2 → PHQ-9/EPDS</td>
<td><em>Major depressive disorder</em></td>
</tr>
<tr>
<td>Initial prenatal visit</td>
<td><em>Persistent depressive disorder</em></td>
</tr>
<tr>
<td>At least once during pregnancy</td>
<td><em>Adjustment disorder</em></td>
</tr>
<tr>
<td>Postpartum visit</td>
<td><em>Depression secondary to medical condition (e.g. hypothyroidism, anemia/substance use)</em></td>
</tr>
<tr>
<td>Well child visits through 12 mos postpartum</td>
<td><em>Depression secondary to another psychiatric disorder (e.g. bipolar disorder, PTSD)</em></td>
</tr>
</tbody>
</table>

**For positive screens, assess safety** (See page 27 for additional guidance)

**Columbia Suicide Severity Rating Scale (CSSRS)** or **Ask Suicide Screening Questions (ASQ)**

Ask about thoughts about harming baby:
“It can be very overwhelming to be a new parent. Sometimes people have upsetting thoughts about hurting their babies, either by accident or on purpose. Have you had thoughts like this?”
Refer to emergency services as needed

**For mild depression:**

Closer monitoring (PHQ-9/EPDS)

Exercise, behavioral activation

Social support

Address sleep issues

Rule out medical causes, bipolar disorder

**Moderate/severe depression:** Add medication and/or psychotherapy; shared decision-making with patient (and partner, as applicable), weighing risks of medications and untreated depression, and considering alternative/non-medication treatments

**Risks of untreated depression:**
*Functional impairment, hospitalization, suicide*
*Poor prenatal care/self-care; smoking, substance use*
*Higher rates of miscarriage, preeclampsia, preterm birth*
*Problems with bonding/attachment*
*Increased hospital stays, more NICU admissions for baby*
*Increased rates of psychiatric disorders in children*

May need increase in dose later in pregnancy

**Alternative/additional treatments:**
*Psychotherapy (CBT, IPT, therapy that has helped in past)*
*Exercise, yoga, bright light, omega-3-fatty-acids (EPA:DHA>1.5)*
*For severe/treatment-resistant depression, consider ECT, TMS, brexanolone, day treatment/inpatient programs*

**Risks of antidepressants:**
*Common and serious side effects*
*No consistent increase in rates of malformations*
*Persistent pulmonary hypertension of the newborn (PPHN; 2.9 vs. 1.8/1000)*
*Neonatal adaptation syndrome in 30%; worse if also taking benzodiazepines*
*Monitor breastfed infants for sedation/poor feeding; case reports of seizures with exposure to bupropion during lactation*

**Goal:**
Treat to remission
Track PHQ-9/EPDS to measure progress/outcome
### Perinatal Depression Medications

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Starting Dose&lt;sup&gt;a&lt;/sup&gt; (mg/day)</th>
<th>Up titration schedule</th>
<th>Use in Pregnancy</th>
<th>Use during Lactation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>SSRIs</strong>&lt;sup&gt;b&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| Citalopram (Celexa) | 10 | Increase to 20 mg/day after one week
Then, increase by 10-20 mg every 4 weeks<sup>c</sup> (max dose 40 mg/day)<sup>d</sup> | SSRIs not associated with increase in malformations | RID<sup>e</sup> < 10%; reports of sedation, fussiness, weight loss in infants; monitor weight gain, behavioral effects |
| Escitalopram (Lexapro) | 5 | Increase to 10 mg/day after one week
Then, increase to 20 mg/day after 4 weeks<sup>c</sup> (max dose 20 mg/day) | May need dosage increase later in pregnancy | RID<sup>e</sup> < 10%; one report of necrotizing enterocolitis; monitor for sedation, irritability |
| Fluoxetine (Prozac) | 10 | Increase to 20 mg/day after one week
Then, increase by 10-20 mg every 4 weeks<sup>c</sup> (max dose 80 mg/day) | Possible increased risk of persistent pulmonary hypertension of the newborn (PPHN); 2.9/1000 vs. 1.8/1000 baseline; lowest risk with sertraline | RID<sup>e</sup> may be > 10%; monitor for behavioral effects, adequate weight gain |
| Paroxetine (Paxil) | 10 | Increase to 20 mg/day after one week
Then, increase dose by 10-20 mg every 4 weeks<sup>c</sup> (max dose 50 mg/day) | Transient neonatal adaptation syndrome (NAS) in 30% of exposed infants | RID<sup>e</sup> generally 5% or less; few adverse effects; monitor for sedation, adequate growth |
| Sertraline (Zoloft) | 25 | Increase to 50 mg/day after one week
Then, increase by 25-50 mg every 4 weeks<sup>c</sup> (max dose 200 mg/day) | Low concentrations in breast milk and infant; RID<sup>e</sup> generally 2% or less; few adverse effects in infants; considered preferred antidepressant in breastfeeding | |
| **SNRIs**<sup>b</sup> | | | | | |
| Duloxetine (Cymbalta) | 30 | Increase dose to 60 mg/day after one week
(max 120 mg/day; rarely need > 60 mg/d) | NAS (see above); possible inc risk of heart defects, miscarriage, postpartum hemorrhage | Few reports; RID<sup>e</sup> < 1%; no adverse effects; monitor for sedation, adequate growth |
| Venlafaxine (Effexor) XR | 37.5 | Increase to 75 mg/day after one week
Then, increase by 37.5-75 mg every 4 weeks<sup>c</sup> (max dose 225 mg/day) | Increased risk for PPHN, NAS (see above); increased risk of gestational hypertension | RID<sup>e</sup> 3-12%; rare adverse effects reported in infants; monitor baby for excessive sedation, adequate weight gain |
| **OTHER**<sup>b</sup> | | | | | |
| Bupropion<sup>f</sup> (Wellbutrin) XL | 150 | Increase by 300 mg/day XL every 4 weeks<sup>c</sup> (max dose 450 mg/day) | No overall inc in malformations
?Inc in LVOT<sup>g</sup> heart defects | RID<sup>e</sup> up to 5.1%
2 reports of seizures in breastfed infants |
| Mirtazapine<sup>h</sup> (Remeron) | 7.5 | Increase to 15 mg qhs after one week
Then, increase by 15 mg every 4 weeks<sup>c</sup> (max dose 45 mg/day) | No increase in malformations NAS (see above) | Few reports; RID<sup>e</sup> < 2%; no adverse effects noted; monitor for behavioral effects, adequate growth |

<sup>a</sup> With comorbid anxiety disorder, use lower starting dose

<sup>b</sup> Antidepressants are associated with increased suicidal thinking and behavior in young adults; monitor closely for worsening or emerging suicidality

<sup>c</sup> As needed to treat continued depressive symptoms

<sup>d</sup> Maximum dose 40 mg/day due to risk of QT prolongation

<sup>e</sup> RID = relative infant dose

<sup>f</sup> Do not give if history of bulimia or seizures; seizure risk limits dose

<sup>g</sup> LVOT = left ventricular outflow tract

<sup>h</sup> Increases appetite, sedating; may help with hyperemesis, insomnia

4/23/23
Perinatal Depression Resources

**Review article:**

**PHQ-9 in multiple languages:**
[https://www.phqscreeners.com](https://www.phqscreeners.com)

**EPDS in multiple languages:**
Edinburgh Postnatal Depression Scale (EPDS) ([perinatalservicesbc.ca](https://perinatalservicesbc.ca))

**Columbia Suicide Severity Rating Scale (CSSRS):**

**Ask Suicide Screening Questions (ASQ):**

**NIMH brochure for patients about perinatal depression (available in English and in Spanish):**

**Mothers and Babies Program**
Information, training, and resources for therapy for perinatal stress and depression based on cognitive behavioral therapy and attachment theory. Website also has information for patients/parents, including how to find a therapist.

**Article about interpersonal therapy (IPT) for postpartum depression:**
This is an article for providers that describes interpersonal therapy (IPT) for postpartum depression, its rationale, structure, and content.

**Article about importance of and prescribing sleep for postpartum depression:**
Perinatal Eating Disorders

Megan Riddle, MD, PhD
Perinatal Eating Disorders

**Prevalence:**
The perinatal period carries increased risk for development of new eating disordered behaviors or recurrence of illness previously in remission. Rates in pregnancy: 0.6-11.5% Rates postpartum: Up to 12.8%

**Risk factors:**
- Personal or family history of eating disorders
- Psychiatric comorbidities
- Trauma history
- LGBTQ

**Screening:**
Personal history of eating disorder (ED) is biggest risk factor for ED symptoms in pregnancy. Include standardized ED screener at intake, such as Eating Disorder Screen for Primary Care:
1. Are you satisfied with your eating patterns?
2. Do you ever eat in secret?
3. Does your weight affect the way you feel about yourself?
4. Have any members of your family suffered with an eating disorder?
5. Do you currently suffer with or have you ever suffered in the past with an eating disorder?
“No” to q1 = abnormal
“Yes” to q2-5 = abnormal
2 abnormal answers = positive screen. Further follow up recommended

**Differential:**
Anorexia nervosa (AN)
Bulimia nervosa (BN)
Binge eating disorder (BED)
Avoidant Restrictive Food Intake Disorder (ARFID)
Other Specified Feeding & Eating Disorder—includes atypical anorexia
Appetite changes secondary to depression
Hyperemesis gravidarum

**Assess Symptoms:**
Frequency, duration, intensity
Restriction—Skipping meals/snacks? Portion sizes?
Are others concerned about intake? Limiting types of food? Eating the same thing every day?
Bingeing—Frequency, amount, eating in secret?
Purging—Vomiting, laxatives, diuretics, diet pills, exercise?

**Medical complications:**
Thorough screen for medical complications
AN/Atypical AN/ARFID: Organ dysfunction related to malnourishment
BN: Complications of purging, electrolyte abnormalities

**Pregnancy Complications:**
AN: hyperemesis, antepartum hemorrhage, preterm birth, microcephaly, SGA
BN: hyperemesis, preterm birth, microcephaly
BED: tobacco use, maternal hypertension, need for c-section, higher gestational weight for age
All: ↑ risk of postpartum depression & anxiety

**Interventions:**
Depend on severity of illness, medical stability, psychiatric comorbidities, ability to modify behavior independently
- Referrals to registered dietitian with ED expertise, therapy, psychiatry
If medical complications of ED or interference with functioning, consider referral to a higher level of care
- Blinded weights with a focus on baby's growth rather than weight gain
- Meal plan with frequent meals throughout the day—even for individuals whose primary ED behavior is identified as bingeing and/or purging, restriction is often a part of this cycle
- Treat psychiatric comorbidities—depression, anxiety, OCD

**Birth control:**
Patients with EDs are at increased risk of unplanned pregnancy. Patients with amenorrhea/oligomenorrhea patients may still be ovulating.
Perinatal Eating Disorder Resources

**Patient resources:**

National Eating Disorder Association:

https://www.nationaleatingdisorders.org/pregnancy-and-eating-disorders

https://www.nationaleatingdisorders.org/blog/decentering-weight-in-prenatal-care

**Further reading:**


Family Assessment

Amritha Bhat, MD
Family Assessment

Key fact: Perinatal mental health problems have effects on gestational parents, non-gestational parents, on the child, and on the family. Emerging evidence indicates high rates of depression among adoptive parents and similar negative effects on the child. Paying attention to infant behavior and caregiver – baby interactions during perinatal care provides an opportunity for promotion of the relationship between caregivers and babies, and, if needed, early intervention.

Caregiver – Baby interaction (Dyadic interaction)

Foundation for cognitive and emotional development and for secure attachment. Caregiver mental health problems can impair dyadic interactions.

Components of dyadic interaction:
- Contingent responsiveness
  - Attention to infant and ability to understand cues
- Respect
  - Acceptance of range of infant behavior
- Empathy
  - Understands infant’s state of mind and reflects it back, helping infant feel understood
- Time
  - Sufficient contact time with baby to develop understanding of baby
- Tolerance for mistakes
  - Tolerates mistakes and allows for repair

Signs of impaired dyadic interaction
- Infant has difficulty signaling/communicating his/her needs to caregiver.
- Caregiver unreliable, inconsistent, or inappropriate in responding to infant’s cues.
- Infant persistently avoids looking at caregiver (or vice versa)
- Infant presents fearful or apprehensive of the caregiver (e.g. looks dazed or flustered when caregiver approaches, freezing, stereotyped behaviors, contradictory behavior such as sideways or aborted approaches to the caregiver)
- Frightening or frightened caregiver behavior (e.g. dissociation, threatening expressions or voice)
- Caregiver experiences infant as rejecting, ‘manipulative’ or vindictive

Perinatal mental health in fathers / non gestational parents:
- Up to 10% experience depression between first trimester and one year postpartum
- Correlated with (and higher rates with) maternal depression.
- May present as irritability, social isolation, drug and alcohol use.
- Depressed fathers are more likely to engage in domestic violence, and discourage their partner from breastfeeding
- There is an association between paternal postpartum depression (PPD) and behavioral and emotional problems in children
- Same screening tools (PHQ-9, EPDS) can be used to identify depression in the non-gestational parent
- Risk factors for paternal depression include not wanting the pregnancy, marital conflict, comorbid maternal prenatal depression, history of depression, and unemployment.
- American Academy of Pediatrics recommendation is to screen caregivers at 1, 2, 4 and 6-month well child visits
- There is a lack of research on perinatal mental health of lesbian gay bisexual transgender and queer parents
Family Assessment Resources

Promoting First Relationships:
Training program for providers who work with parents and young children
www.pfrprogram.org

Research-based Bringing Baby Home workshops:
https://www.gottman.com/parents/

Mount Sinai Parenting Guides:
Information on infant behavior and development for parents
https://parenting.mountsinai.org/parent-guides/

Information for fathers from the American Academy of Pediatrics:
A special message to new dads (American Academy of Pediatrics)
Hormones and Mood

Amritha Bhat, MD
Hormones and Mood

**Key fact:** Certain individuals may be vulnerable to dysregulation of mood during times of hormonal fluctuation (windows of vulnerability such as menarche, premenstrual, postpartum, menopause).

**Premenstrual Dysphoric Disorder (PMDD)**
Affects 5 - 12% women. Always rule out underlying mood disorder with premenstrual worsening, use prospective recording of symptoms for accurate diagnosis (Daily Record of Severity of Problems OR Premenstrual Symptoms Screening Tool)

Diagnostic criteria:
1. Symptoms in the majority of menstrual cycles, present in the week before menses, improve after the onset of menses, absent 1 week post menses. At least one of
   - Marked mood lability
   - Marked irritability or anger or increased interpersonal conflicts.
   - Marked depressed mood, feelings of hopelessness, or self-deprecating thoughts
   - Marked anxiety, tension, and/or feelings of being keyed up or on edge
2. One (or more) of the following symptoms, to reach a total of five symptoms when combined with above symptoms
   - Decreased interest in usual activities
   - Subjective difficulty in concentration
   - Lethargy, easy fatigability, or marked lack of energy
   - Marked change in appetite; overeating; or specific food cravings
   - Hypersomnia or insomnia
   - A sense of being overwhelmed or out of control
   - Physical symptoms such as breast tenderness or swelling, joint or muscle pain, a sensation of “bloating,” or weight gain.
3. Symptoms associated with clinically significant distress or interference with work, school, usual social activities, or relationships.

**Hormonal contraception**
- Individuals with a history of depression should monitor mood closely after starting a hormonal contraceptive.
- Risk of mood worsening higher in adolescents
- If possible, avoid long-acting hormonal contraceptives in those with mood disorders

**Hormonal contraception and psychotropic drug interactions:**
- **Lamotrigine:** Oral contraceptives can reduce the serum levels of lamotrigine: dose of lamotrigine may need to be increased.
  At higher baseline doses of lamotrigine, monitor for side effects / toxicity in pill free week.
- **Carbamazepine, Oxcarbazepine and Topiramate** can decrease plasma levels of hormonal contraceptives and adversely affect their effectiveness
- **SSRIs** - no effects

**Hormonal treatment for Postpartum Depression (PPD): Brexanolone:** Intravenous formulation of allopregnanolone. FDA approved for PPD. 60-hour iv infusion in certified facility. Improvement in depression within a week, benefit lasting through one month follow up in clinical trials. Side effects sedation, loss of consciousness. Safety in breastfeeding not established. Oral formulation, zuranolone, in clinical trials.

**Hormonal treatment for perimenopausal depression:**
Hormone Replacement Therapy for prevention of depression may be considered in early menopausal transition for
- women with histories of major depression
- those with more severe vasomotor symptoms
- stressful life events occurring in the prior 6 months

Hormonal treatment for perimenopausal depression in women who don't want to take antidepressants or do not tolerate / respond to antidepressants, or as augmentation of SSRIs/SNRIs: Transdermal estradiol (plus progestin as indicated)
- **Risks:** breast cancer, thromboembolism, cardiovascular disease.
Infertility

Elizabeth Richards, MD
Infertility

Overview
Infertility
- Inability to conceive after 12 months of unprotected sex under age 35 (6 months if over age 35)
- Encompasses physical, hormonal, or reproductive circumstances.
  - Mayer-Rokitansky-Küster-Hauser (MRKH) Syndrome: underdeveloped or absent uterus makes natural conception and childbirth impossible.
  - Social infertility: obstacles due to societal or lifestyle factors rather than medical reasons
    - Elevating this to a treatable medical condition helps justify the use of assisted reproductive technology for these individuals.

Incidence/Prevalence: between 6% and 18% in the US (increases with age)

Mental Health Challenges Associated with Infertility
- Infertility has a profound impact on women's mental health, leading to higher distress levels compared to their male partners.

- People often experience anxiety, guilt, anger, hopelessness, disappointment, sexual dysfunction, social isolation, diminished self-esteem, and depression.

- Rates of depression are significantly higher (15%-54%) in infertile couples seeking treatment compared to fertile controls, while anxiety rates (8%-28%) surpass those in the general population.

- More invasive medical treatments are correlated with increased anxiety and depression. Fertility medications can impact mood.

- Infertility can strain relationships, causing conflict, communication difficulties, and sexual dysfunction. Physicians must acknowledge the impact on both individuals and couples.

Stress is prevalent among individuals facing infertility, especially during treatment.

- Hormonal fluctuation, cycles of hope and disappointment, feeling loss of control.
- Psychological burden and stress prevent 1 in 10 patients from starting infertility treatment.
- Monitor for high levels of stress during oocyte retrieval, embryo transfer, and the waiting period before the pregnancy test.
Infertility (Continued)

Grief in infertility is complex, involving various types of losses.

- **Pregnancy-related losses**: biochemical pregnancy, miscarriage/stillbirth, ectopic pregnancy, fetal anomaly.
- Assisted Reproductive Technology alters the experience of pregnancy loss.
  - Early ultrasound with heartbeat at 6 weeks.
  - Visual embryo identification fosters attachment.
- **Infertility-specific losses**: failed IUI/IVF, loss of frozen eggs/embryos, absence of normal embryos for transfer, reliance on donor gametes.
- Disenfranchised grief due to shame, stigma, lack of acknowledgment or support, absence of grieving rituals.
- Managing grief can be particularly challenging during holidays, family gatherings, or social events focused on children and family.

Providers should be aware of psychological symptoms that may arise during pregnancy after infertility.

- Heightened anxiety and vigilance
- Persistent fear of potential loss
- Reluctance to share pregnancy news
- Ambivalence and guilt
- Feelings of isolation, not fitting into the infertile or fertile world
- Fear of expressing negative thoughts or experiences
- Denial, avoiding emotional investment in the pregnancy
- Increased risk of depression

Role of Mental Illness in Causation of Infertility

- Causal role of psychological factors and infertility remains debated.
- Depression's potential direct impact on infertility: elevated prolactin, HPA axis disruption, thyroid dysfunction, regulation of luteinizing hormone.
- Stress and depression-related changes in immune function may impact reproduction.
- More research needed to separate depression's direct effects from associated behaviors like low libido, smoking, and alcohol use.
- Cumulative stress of recurrent depression and anxiety may play a causative role, given the similar physiological changes seen with stress.

It's crucial recognize that individuals with mental health issues conceive, emphasizing the importance of balancing mental health treatment during infertility treatment. This helps reduce self-blame and guilt, dispelling the misconception that infertility solely results from stress.
Infertility Treatment

### Non-pharmacological strategies
- Individual and couples in counseling during fertility treatments reported significantly lower depression, anxiety, and distress
- Cognitive-behavioral therapy (CBT) stands out as one of the most effective
- Support groups
- Only 10-34% of patients utilize these resources, highlighting an area for improvement.

### Pharmacological strategies
- Little data regarding pharmacologic treatment of patients with infertility.
- Medications can be an important option for moderate to severe depression in the context of infertility and its treatment.
- No evidence to suggest that commonly used antidepressants have negative effects on fertility.
- Significant amount of data to support the safety and efficacy of using antidepressants during pregnancy (see other care guides for details)

Consider referring patients to mental health professionals specialized in infertility distress.

Infertility Resources for Patients

**Resolve, The National Infertility Association**: City-specific support groups

**Hope and Support**: Seattle-based Facebook support group

**Club Hope**: Washington and Oregon support group with newsletter service

**ORM Fertility**: Bellevue and Portland fertility clinics offering multiple support groups

**Livestrong Fertility**: Infertility after cancer

**The American Society for Reproductive Medicine** (ASRM)

**FertilityIQ**: Patient reviews on fertility clinics, doctors, and treatments

**The Bumpin Project**: Infertility & assisted reproduction challenges

**Creating a Family**: Podcasts, articles, and an online community for infertility support

**Fertility Within Reach**: Insurance, legal, and financial aspects of infertility treatment

**Infertility Out Loud** (Podcast)

**The Blossom Method**: Emotional and psychological well-being during the fertility journey

**Mental Health America**: Non-profit organization, mental health support, including infertility-related issues

**The Infertility Support Group**: Facebook Group

**Apps**: Calm, Headspace, Mindful IVF, Insight Timer, Happify, Mindfulness Daily
Perinatal Obsessive-Compulsive Disorder (OCD)

Carmen Croicu, MD
**Perinatal OCD**

Perinatal period is a high-risk time for the onset or exacerbation of OCD and the risk is higher in the postpartum period than during pregnancy; rates of postpartum OCD exacerbation between 25% and 75%. Consider screening for OCD in patients presenting with anxiety and depression (high rates of comorbidity with anxiety disorders and MDD).

### Screening for OCD symptoms and intrusive thoughts of harming the baby

- Some useful screening questions:
  
  "Are you having any thoughts that keep bothering you that you’d like to get rid of but cannot?"

  "Do you do things over and over again because you feel anxious if you don't (for example, checking on your baby, washing your hands)?"

  "Sometimes parents have scary thoughts or images of harm coming to their baby, accidentally or deliberately. Have you had any thoughts like that?"

- positive OCD screen should be followed by a diagnostic evaluation

- **Yale-Brown Obsessive-Compulsive Scale (Y-BOCS):** interviewer-rated scale, 10 items, gold standard for symptom severity measurement, > 25-35% decrease in score = response to treatment, < 8 = remission of OCD

### Unique features of perinatal OCD

**Pregnancy:** gradual onset
- contamination obsessions and cleaning rituals (frequent)

**Postpartum:** rapid onset (within 4 weeks)
- frequent occurrence of aggressive obsessions and intrusive thoughts/fears of accidentally harming the baby
- avoidance behaviors (e.g. bathing), mental rituals, compulsive checking of infant
- contamination obsessions and cleaning compulsions, checking compulsions

### Risks of untreated OCD

- adverse pregnancy outcomes (preterm delivery, low-birth weight, preeclampsia)
- reduced ability to care for the newborn, negative impact on mother-infant bonding

### Differential diagnosis of intrusive thoughts about harming the baby

**OCD:** thoughts of harm are ego dystonic (foreign/disturbing to the patient, inconsistent with their beliefs and values); feelings of guilt and shame, good insight, compulsive rituals, no risk of infant-harming behaviors

**Postpartum psychosis:** thoughts of harm are ego syntonic (acceptable to the patient); poor insight, no feelings of guilt and shame, delusions and/or hallucinations, no compulsive rituals, increased risk of harm, never leave the mother alone with the baby

**Postpartum depression:** associated depressive symptoms, no delusions and/or hallucinations or mood-congruent psychotic symptoms, low risk of harm but high risk with associated psychotic symptoms
**Guidelines for management of perinatal OCD**

<table>
<thead>
<tr>
<th>First-line evidence-based therapies: CBT, specifically exposure and response prevention (ERP), SSRIs</th>
</tr>
</thead>
<tbody>
<tr>
<td>CBT/ERP: 1st line treatment for mild-moderate OCD, highly effective</td>
</tr>
<tr>
<td>CBT/ERP + SSRI: for moderate-severe OCD</td>
</tr>
<tr>
<td>SSRIs: preferred when the severity of symptoms prevents the mother from engaging in CBT/ERP</td>
</tr>
<tr>
<td>Other interventions: psychoeducation provided to mother and families about the nature of infant-focused obsessions</td>
</tr>
</tbody>
</table>

**Pharmacological treatment:**

<table>
<thead>
<tr>
<th>SSRIs: 1st line, no data suggesting one SSRI is superior to another, higher dose than used for depression</th>
</tr>
</thead>
<tbody>
<tr>
<td>See <em>antidepressant table in the depression care guide</em></td>
</tr>
</tbody>
</table>

**Fluvoxamine:** limited data, no major malformations with exposure (n~500); low levels in breastmilk (dose <300 mg/daily), and not expected to cause adverse effects in the breastfed infant; monitor infants for diarrhea, vomiting, decreased sleep, and agitation.

**Clomipramine:** limited data and less well tolerated compared to SSRI's, increased risk of major malformations (OR 1.4) including cardiovascular defects (OR 1.6), more severe and prolonged neonatal adaptation syndrome; limited data about risks in lactation, no adverse effects in 4 infants

**Treatment-resistant OCD**

- address specific treatment for comorbid disorders  
- add CBT/ERP (if not already initiated) to SSRI  
- longer trial of SSRI, dose optimization, switch to a new SSRI  
- augmentation of SSRI with atypical antipsychotics: very limited data, quetiapine augmentation (average dose of response 100mg daily) after inadequate response to SSRI (n=17 postpartum women)  
- initiate psychiatric referral or psychiatric consultation
Perinatal OCD Resources

**Review articles:**


**Patient manuals:**

Break Free from OCD: Overcoming Obsessive Compulsive Disorder with CBT Paperback – September 1, 2012 by Dr. Fiona Challacombe, Dr. Victoria Bream Oldfield, Professor Paul Salkovskis: [https://www.amazon.com/Break-Free-OCD-Overcoming-Compulsive/dp/0091939690/ref=sr_1_1?dchild=1&qid=1618855536&refinements=p_27%3ADr.+Fiona+Challacombe&s=books&sr=1-1&text=Dr.+Fiona+Challacombe](https://www.amazon.com/Break-Free-OCD-Overcoming-Compulsive/dp/0091939690/ref=sr_1_1?dchild=1&qid=1618855536&refinements=p_27%3ADr.+Fiona+Challacombe&s=books&sr=1-1&text=Dr.+Fiona+Challacombe)


**Websites for patients:**

Royal College of Psychiatrists’ page on Perinatal OCD [https://www.rcpsych.ac.uk/mental-health/problems-disorders/perinatal-ocd](https://www.rcpsych.ac.uk/mental-health/problems-disorders/perinatal-ocd)

International OCD Foundation page with fact sheets, brochures, apps, books about OCD; guidance in finding treatment [https://iocdf.org/](https://iocdf.org/)

Perinatal Posttraumatic Stress Disorder (PTSD)

Carmen Croicu, MD
# Perinatal PTSD

**Common:** prevalence 4-6%; higher rates 1-6 months postpartum; 18% if risk factors for PTSD; rates of PTSD are as high as 24% for women from racial minority groups, teens, and those of lower socioeconomic status

<table>
<thead>
<tr>
<th>Risk factors</th>
<th>Screening</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subjective experience of childbirth (negative emotions or experience of labor, loss of control, fear of childbirth for self and/or baby)</td>
<td>PTSD Checklist Civilian (PCL-5): 20-item self-report checklist of PTSD symptoms (based closely on the DSM-5 criteria), cutoff score between 31-33 indicative of probable PTSD, used in the perinatal population but not specifically validated</td>
</tr>
<tr>
<td>Maternal mental health (prenatal depression, perinatal anxiety, postpartum depression)</td>
<td>Screen for comorbidities: depression (highly comorbid), anxiety, substance use</td>
</tr>
<tr>
<td>Trauma history and PTSD (previous traumatic events, childhood sexual trauma, prenatal PTSD, previous traumatic birth experience)</td>
<td></td>
</tr>
<tr>
<td>Delivery mode and complications (emergency C-section, complications with pregnancy and/or baby)</td>
<td></td>
</tr>
</tbody>
</table>

**Assessing DSM-5 criteria for PTSD**

Traumatic event/trauma exposure  
Duration >1 month, Distress/Impairment

**Symptom criteria**

- ≥1 intrusion (flashbacks, nightmares) and
- ≥ 1 avoidance (trauma reminders) and
- ≥ 2 cognitions/mood (detachment, anhedonia, negative emotions) and
- ≥2 arousal (hypervigilance, sleep difficulties)

**Risks of untreated PTSD**

**Risks to mother:** avoidance of prenatal care and postpartum checks, postpartum depression, substance use, preterm labor, fear of childbirth (tokophobia), pregnancy complications (preeclampsia, gestational diabetes)

**Risks to fetus:** lower birth weight, preterm birth, negative impact on mother-infant bonding, lower rates of breastfeeding

**Guidelines for management of perinatal PTSD (if PCL-5>33 and/or clinical diagnosis of PTSD)**

**First-line evidence-based therapies:** SSRIs, Trauma-focused psychotherapies (TFPT)  
Initiate SSRI if TFPT not available, not preferred or not appropriate  
Other interventions: education, Imagery rehearsal therapy (IRT), CBT-I, non trauma-focused therapy, social support

**Evidence-based trauma-focused psychotherapies:**

- Exposure therapy (ET): effective in postpartum women regardless of whether birth was objectively traumatic
- Trauma-Focused Cognitive Behavioral Therapy (TFCBT): effective for women at risk for experiencing a traumatic birth
- Eye Movement Desensitization and Reprocessing (EMDR): could be especially effective for hyperarousal symptoms
Perinatal PTSD (Continued)

Avoid starting prazosin (adjunctive agent for PTSD-related nightmares) during pregnancy and lactation:

- Few reports of prazosin use for hypertension treatment during pregnancy
- No human data in pregnancy; based on experimental animal studies, therapy during pregnancy with prazosin is not expected to increase the risk of congenital anomalies
- No reports examining effects of prazosin during lactation; the manufacturer has reported that “one mother excreted at most 3% of the dose into her breastmilk.”
- Case report of a fetal demise attributable to maternal hypotension and caused by an increased dose of prazosin
- If prazosin is essential to maintain psychiatric stability it is very important to inform the woman about the risks and benefits of this medication; greater bioavailability and slower elimination in pregnant women; lower dose than usual if prescribed during pregnancy; very close monitoring of blood pressure

Pharmacological treatment:
- SSRIs (sertraline, fluoxetine)
- Venlafaxine
- See medication table in Perinatal Depression Care Guide for information about SSRIs, venlafaxine

Interventions not effective:
- debriefing, counseling, trazodone, benzodiazepines
Perinatal PTSD Resources

**Review Articles:**


**PTSD Checklist for DSM-5 (PCL-5):**

[https://istss.org/clinical-resources/assessing-trauma/ptsd-checklist-dsm-5](https://istss.org/clinical-resources/assessing-trauma/ptsd-checklist-dsm-5)
Pregnancy Loss

Aba Nduom, MD
Pregnancy Loss

-There is a wide range of normal reactions to pregnancy loss. Some people will conceptualize it as their baby died and will even assign a sex and choose a name. Others will be more detached and focus on believing that their body did what it had to do. The depth of grief is only loosely correlated with the facts of the pregnancy and the loss.

- Always take cues from the patient, and even ask them what they would like to hear now. Ask both open ended and close ended questions. “What questions/fears do you have?” “What worries you the most right now?” “Would you like to discuss trying to conceive again?” If possible, offer to schedule another follow up appointment to answers questions they might not be ready to discuss right now.

-Most patients take comfort in being told that miscarriage is common and that there was nothing they did to cause it. However, few patients take comfort in being told that their body did the right thing by miscarrying a potentially abnormal pregnancy, as they see their body as what created the abnormal pregnancy in the first place.

- When the evidence base is slim or controversial, offer the patient clear options and rationale rather than absolute guidelines. For example, “Most people choose to wait for at least one period after their miscarriage before trying to conceive again. It makes it easier to date the next pregnancy and helps reassure you that your body has recovered. It is also okay to take more time to grieve and rest. There is no data that shows that it is easier to conceive immediately after a miscarriage.”

- Be honest when recommendations are based in what insurance may or may not cover, as the reassurance from certain tests or procedures (for example, testing the products of conception after a first miscarriage) may be worth the out-of-pocket cost for some patients.

- Most women do not require psychiatric care after a single miscarriage, but some do. These losses can either cause a decompensation of a previous mental health diagnosis or can be the initial precipitation event for a new diagnosis. Consider having a standard list of self-help and professional resources to offer routinely, especially if the patient will not be having a follow up appointment to further discuss the miscarriage.

-For appointments related to pregnancy or infant loss, when possible, try to room the patients quickly to avoid leaving them in the waiting room. While they will not be able to avoid pregnant women forever, returning to your clinic or the hospital is often very stressful, and these little policy changes can make a world of difference for them. If possible, avoid rooming them in the same room where they found out about their loss. You can also consider turning down the volume on dopplers for heartbeat checks so that they are less likely to be heard between rooms.

-If a partner is present, remember to address them and their possible grief as well.
Additional Considerations

Terminations for Medical Reasons (TFMR): Patients who decide to terminate a pregnancy for medical reasons (either for their own health or due to medical findings about the fetus), typically experience these losses similar to those who experience spontaneous pregnancy losses and stillbirths, but often with an added layer of potential social stigma. These are situations in which the pregnancy was very much wanted, and TFMR often happens at a point in the pregnancy where they have either socially announced their pregnancy or were about to. Most parents who choose to TFMR are confident that they made the right decision, and also feel deep grief about their loss.

Elective Terminations: Several studies have shown that when elective terminations (terminations for social/personal reasons) are pursued without coercion, there is minimal to no long-term mental health impact. At the same time, some people, especially those who feel that they may have made a different decision if social or financial situations were different at the time of the pregnancy, may have more complicated feelings in the aftermath. Follow your patient’s lead in how they talk about the termination, and do not assume guilt or emotional conflict.

Pregnancy After Loss: Pregnancy after loss often comes with a mix of joy and fear. Not only is there usually anxiety that the same type of loss may happen again, but often times, people have heightened anxiety about other potential adverse outcomes that can happen during pregnancy, or postpartum. Some people feel significant relief once they pass the timeframe of their previous loss(es), but this is not the case for everyone. And in the case of those who experienced stillbirth, the entire pregnancy may be experienced as a time of concern.

Common Medical Terms

Chemical/Biochemical Pregnancy – A very early miscarriage before anything can be seen on ultrasound. More commonly noticed these days due to the combination of the increased sensitivity of home pregnancy tests, and more people tracking their cycles more closely, and therefore testing earlier.

Miscarriage/Spontaneous Abortion – Pregnancy loss prior to 20 weeks gestational age. Most commonly happens prior to 10 weeks.

Threatened Miscarriage/Threatened Abortion – Bleeding during early pregnancy. May resolve without any consequences or may be the precursor to a miscarriage.

Missed Miscarriage/Missed Abortion – Fetal demise prior to the 20th week without spontaneous expulsion of the products of conception.

Blighted Ovum – A pregnancy characterized by the development of the gestational sac without an embryo.

Recurrent Pregnancy Loss – (old diagnosis: HabitualAborter) The threshold number of losses varies from 2 to 3.

Stillbirth – Pregnancy loss after the 20th week.
Incidence

- Early Pregnancy loss (within the first trimester) is most common, and may be up to 31% especially when biochemical pregnancies are taken into account. Once a pregnancy is visualized on ultrasound with a reassuring heartbeat, the rates drop significantly.

- The rate of second trimester miscarriages is less than 1%.

- The stillbirth rate in the US is 6.0 per 1000 births, approximately 50% of which occur between 20 and 27 weeks gestation.

- With each subsequent pregnancy loss, the risk of having another one increases.
Pregnancy Loss Resources

Local organizations:

Parent Support of Puget Sound
Support groups and resources for those who have experienced miscarriage or infant loss.
http://psopugetsound.org/

National organizations:

RESOLVE: 1-866-668-2566
A national helpline providing peer support for people experiencing infertility or miscarriage.
https://resolve.org/

Virtual support groups:

Postpartum Support International (PSI) online support groups
Online support groups for pregnancy and infant loss and fertility challenges
https://www.postpartum.net/get-help/psi-online-support-meetings/

Workbooks:

Coping With Infertility, Miscarriage, and Neonatal Loss: Finding Perspective and Creating Meaning by Amy Wenzel

Books:

The Brink of Being: Talking About Miscarriage by Julia Bueno
https://www.amazon.com/dp/B07JVZGX1C/

The Miscarriage Map: What To Expect When You Are No Longer Expecting by Sunita Osborn
https://www.amazon.com/Miscarriage-Map-Expect-Longer-Expecting-ebook/dp/B07W4RV5DQ

You Are Not Alone: Love Letters From Loss Mom to Loss Mom by Emily Long

About What Was Lost: Twenty Writers on Miscarriage, Healing, and Hope by Jessica Berger Gross

Empty Cradle, Broken Heart: Surviving the Death of Your Baby by Deborah Davis (Author)
https://www.amazon.com/Empty-Cradle-Broken-Heart-Surviving-ebook/dp/B01MXLRP37/

More about stillbirth, but some women who miscarry find reading about that helpful as well:
An Exact Replica of a Figment of My Imagination: A Memoir by Elizabeth McCracken
https://www.amazon.com/Exact-Replica-Figment-My-Imagination-ebook/dp/B001DR7K02/
**Articles:**

Eighteen Attempts at Writing About a Miscarriage by Alice Bradley

Dear Newly Bereaved Parent by Angela Miller

The Japanese Art of Grieving a Miscarriage by Angela Elson

Mourning my Miscarriage by Peggy Orenstein

The Heartbreak of Almost: A Modern Miscarriage Story by Nora McInerny

That Time We Didn't Become Parents on Social Media by Kelly Ferraro
[https://medium.com/@kellyferraro/that-time-we-didn-t-become-parents-on-social-media-bf18b1fb32a0#.tanuitv9x](https://medium.com/@kellyferraro/that-time-we-didn-t-become-parents-on-social-media-bf18b1fb32a0#.tanuitv9x)

The Internet Still Thinks I'm Pregnant by Amy Pittman

“There Was No Child, I Told Myself”: Life and Marriage after Miscarriage by Christen Decker Kadkhodai

**Podcasts:**

Terrible, Thanks for Asking (Not specifically about miscarriage, but generally about coping with loss and hardship)

Sisters in Loss
[https://sistersinloss.com/blog/](https://sistersinloss.com/blog/)

The Still Mama Tribe (again, more about stillbirth but some episodes about miscarriage)
[https://thestillmamatribe.wixsite.com/stillmamatribe/podcast](https://thestillmamatribe.wixsite.com/stillmamatribe/podcast)

**Specific Episodes:**

Katie's Crib: Miscarriages: You are not Alone with Amy Mass & Jackie Seiden

Dear Sugars: Redux: When Your Loved Ones Just Don’t “Get It”
Postpartum Psychosis

Ramanpreet Toor, MD
**Postpartum Psychosis**

**Prevalence**: rare, 1-2 per 1000 births. Symptoms occur within 2 weeks of delivery. Sudden onset and rapid deterioration. PSYCHIATRIC EMERGENCY!!

<table>
<thead>
<tr>
<th>Risk factors</th>
<th>Etiology</th>
<th>Differential Diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primiparity</td>
<td>Unclear</td>
<td>Postpartum depression</td>
</tr>
<tr>
<td>Prior postpartum psychosis</td>
<td>Since childbirth is trigger, mechanism of onset is considered to be related to specific physiological changes leading to disease in genetically vulnerable population.</td>
<td>Postpartum OCD (Obsessive-Compulsive Disorder)</td>
</tr>
<tr>
<td>History of mania (bipolar disorder) or psychosis</td>
<td></td>
<td>Other medical cause:</td>
</tr>
<tr>
<td>Family history of postpartum psychosis</td>
<td></td>
<td>Infections</td>
</tr>
<tr>
<td>Discontinuation of medications</td>
<td></td>
<td>Autoimmune</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Medication reaction (steroids)</td>
</tr>
</tbody>
</table>

**Clinical Presentation**
Usually within 2 weeks after delivery; symptoms change rapidly

**Early Symptoms:**
Insomnia/sleep deprivation, Anxiety, Mood fluctuations, Irritability

**Subsequent Symptoms:**
- Disorganization
- Abnormal thought content (delusions, hallucinations)
- Obsessive thoughts related to infant, childbirth
- Delirium—disorientation, disturbance in attention, cognition, disorganized behavior. All symptoms developed over short time.
- Thoughts of harm to self or infant

**Laboratory Testing**
Complete Blood Count (CBC)
Comprehensive Metabolic Panel (CMP)
Thyroid: TSH, T4, Thyroid Peroxidase (TPO) antibodies
Ammonia levels
Urinalysis
**Imaging:**
If neurological symptoms

**Risk Assessment**
High risk of self or infant harm
Inquire about thoughts of self-harm or harm to infant
Suicide risk: Screen with C-SSRS
Risk of infant harm: First, determine if thought of harming infant is an intrusive thought (unwanted negative thought that is frequent and difficult to dismiss) or infanticidal ideation (due to a psychosis).
Ask questions assessing specific content of the thought, and emotional and behavioral responses to thoughts.

**Decisional capacity assessment**
Assess capacity to make decisions for any procedures during pregnancy and postpartum. Also assess capacity to parent if psychotic symptoms are present

**Treatment:**
Inpatient psychiatric admission

**Medication**
- Antipsychotics: Atypical > Typical
- Lithium: Combined with antipsychotic or monotherapy, especially in bipolar disorder
- Benzodiazepine: promotes sleep, short-term treatment, preferably one with short half-life like lorazepam

**Prevention**
Pharmacological Prophylaxis:
- In chronic bipolar disorder: during pregnancy and postpartum
- In postpartum psychosis limited to postpartum periods only: Start immediately postpartum

Adequate sleep
Family support
Close monitoring by providers (OB and pediatrician)

**Long-term outcomes after first onset postpartum psychosis:**
- 56.7% develop lifelong severe psychiatric disorder, most often bipolar disorder
- 6.1% have recurrent psychosis only during the postpartum period
- 36% with no recurrence
Postpartum Psychosis References


## Antipsychotic Medication Table

<table>
<thead>
<tr>
<th>Typical Antipsychotic (Brand Names)</th>
<th>Therapeutic dose range for psychosis</th>
<th>Pregnancy</th>
<th>Breastfeeding</th>
</tr>
</thead>
<tbody>
<tr>
<td>Haloperidol (Haldol)</td>
<td>4-20 mg/day Doses can be higher in more severe symptoms</td>
<td>Higher risk for extrapyramidal signs</td>
<td>&lt;10 mg daily produce low levels and no adverse effects Negative effects when combined with other antipsychotics Monitor drowsiness and developmental milestones</td>
</tr>
<tr>
<td>Atypical Antipsychotics (Brand Names)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Risperidone (Risperdal)</td>
<td>3-6 mg</td>
<td>Effective for psychosis, acute agitation Possible increase risk of cardiac malformation</td>
<td>Doses up to 6 mg produced low levels in milk Limited data</td>
</tr>
<tr>
<td>Quetiapine (Seroquel)</td>
<td>ER:400-800 mg IR: 300-750 mg</td>
<td>Lowest placental transfer Risk of metabolic syndrome</td>
<td>Doses up to 400 mg produced low levels in milk No adverse effects noted</td>
</tr>
<tr>
<td>Aripiprazole (Abilify)</td>
<td>10-30 mg</td>
<td>Lower risk of metabolic syndrome Risk of akathisia Possible low risk of neurodevelopment disorder (Straub et al 2022)</td>
<td>Doses up to 15 mg produced low levels in milk It can LOWER SERUM PROLACTIN</td>
</tr>
<tr>
<td>Olanzapine (Zyprexa)</td>
<td>10-20 mg</td>
<td>Effective for mood stabilization, psychosis Sedating Metabolic syndrome! Highest placental transfer: 72.1%</td>
<td>Doses up to 20 mg showed low levels in milk Recommended first line in breastfeeding</td>
</tr>
<tr>
<td>Ziprasidone (Geodon)</td>
<td>40-80 mg</td>
<td>Lower risk of metabolic syndrome Limited data</td>
<td>Other antipsychotics preferred given very little data</td>
</tr>
<tr>
<td>Clozapine (Clozaril)</td>
<td>300-450 mg/day</td>
<td>Effective for treatment resistant schizophrenia Risk of agranulocytosis for which close monitoring is needed</td>
<td>Limited data Sedation and risk of agranulocytosis</td>
</tr>
</tbody>
</table>

No human data for newer antipsychotics including: Asenapine, Cariprazine, Lurasidone, Brexiprazole.
Perinatal Schizophrenia

Ramanpreet Toor, MD
# Perinatal Schizophrenia

## Epidemiology:
Peak onset childbearing age (26-32 years), almost 50% with diagnosis get pregnant. Risk of relapse in pregnancy if untreated. Most pregnancies are unplanned, poor prenatal care, high risk of rapid repeat pregnancy.

## Diagnostic criteria:
2 or more of following
- Delusions
- Hallucinations
- Disorganized thinking
- Grossly disorganized or catatonic behavior
- Negative symptoms

Markedly low level of functioning in one or more major areas compared to before symptoms
Symptoms continue for 6 months or more

## Pregnancy complications:
More frequent smoking, alcohol and substance addictions. More Gestational hypertension, 2-fold increased risk of GDM, Genito-urinary infection, IUGR, threatened pre-term labor

## Delivery Complications:
Stillbirths or medical abortions, Unexplained fetal/infant death, fetal deaths from severe neurological malformation

## Neonatal/neurodevelopment complications:
Low birth weight, SGA, Preterm birth, development delay, higher risk of intellectual disability, Congenital malformations (6 studies), behavioral problems

## Risk assessment:
Worsening symptoms can lead to denial of pregnancy, poor antenatal care. Thoughts about harming baby related to command hallucinations or delusions possible. Important to monitor psychotic symptoms and evaluate safety throughout pregnancy and postpartum.

### Columbia Suicide Severity Rating Scale (C-SSRS)
Evaluate for thoughts about harming baby: Ask about hallucinations and specifically about command hallucinations (for example voices can tell patients to harm baby). Ask questions assessing specific content of the thought, and emotional and behavioral responses to thoughts.

### Decisional capacity assessment:
Assess capacity to make decisions for any procedures during pregnancy and postpartum. Also assess capacity to parent if psychotic symptoms present.

## Assessment of level of functioning, quality of parenting ability and need for social work or child protective services involvement

## Treatment:
Individual risk-benefit analysis. In schizophrenia benefits of psychopharmacology mostly outweigh the risk. Increased risk of exacerbation of symptoms for 1 year postpartum so close monitoring recommended.

### Psychopharmacology:
- **Antipsychotics**
  - High potency typical antipsychotics preferred (e.g. Haloperidol)
  - Atypical antipsychotics: start quetiapine or olanzapine if not on medication
- **Long-Acting Injections**: Very limited data. Consider continuing if patient stable prior to pregnancy. Levels more stable in pregnancy.
- **Psychotherapy**: More supportive approach and CBT can also help in psychosis.
References


Uguz F. *Antipsychotic use during pregnancy and the risk of gestational diabetes mellitus. A systematic review*. 2019

Ncrptraining.org
## Antipsychotic Medication Table

<table>
<thead>
<tr>
<th>Typical Antipsychotic (Brand Names)</th>
<th>Therapeutic dose range for psychosis</th>
<th>Pregnancy</th>
<th>Breastfeeding</th>
</tr>
</thead>
<tbody>
<tr>
<td>Haloperidol (Haldol)</td>
<td>4-20 mg/day Doses can be higher in more severe symptoms</td>
<td>Higher risk for extrapyramidal signs</td>
<td>&lt;10 mg daily produce low levels and no adverse effects Negative effects when combined with other antipsychotics Monitor drowsiness and developmental milestones</td>
</tr>
<tr>
<td>Risperidone (Risperdal)</td>
<td>3-6 mg</td>
<td>Effective for psychosis, acute agitation Possible increase risk of cardiac malformation</td>
<td>Doses up to 6 mg produced low levels in milk Limited data</td>
</tr>
<tr>
<td>Quetiapine (Seroquel)</td>
<td>ER:400-800 mg IR: 300-750 mg</td>
<td>Lowest placental transfer Risk of metabolic syndrome</td>
<td>Doses up to 400 mg produced low levels in milk No adverse effects noted</td>
</tr>
<tr>
<td>Aripiprazole (Abilify)</td>
<td>10-30 mg</td>
<td>Lower risk of metabolic syndrome Risk of akathisia Possible low risk of neurodevelopment disorder (Straub et al 2022)</td>
<td>Doses up to 15 mg produced low levels in milk It can LOWER SERUM PROLACTIN</td>
</tr>
<tr>
<td>Olanzapine (Zyprexa)</td>
<td>10-20 mg</td>
<td>Effective for mood stabilization, psychosis Sedating Metabolic syndrome! Highest placental transfer: 72.1%</td>
<td>Doses up to 20 mg showed low levels in milk Recommended first line in breastfeeding</td>
</tr>
<tr>
<td>Ziprasidone (Geodon)</td>
<td>40-80 mg</td>
<td>Lower risk of metabolic syndrome Limited data</td>
<td>Other antipsychotics preferred given very little data</td>
</tr>
<tr>
<td>Clozapine (Clozaril)</td>
<td>300-450 mg/day</td>
<td>Effective for treatment resistant schizophrenia Risk of agranulocytosis for which close monitoring is needed</td>
<td>Limited data Sedation and risk of agranulocytosis</td>
</tr>
</tbody>
</table>

No human data for newer antipsychotics including: Asenapine, Cariprazine, Lurasidone, Brexiprazole.
Sleep in the Perinatal Period

Katherine Palm-Cruz, MD
Managing Sleep Disturbances in the Perinatal Period

**Sleep disturbances**

→ very common during pregnancy: Up to 78% of women (worse in third trimester)

→ fragmented sleep common postpartum

Poor sleep during pregnancy associated with: depression, SGA, pre-eclampsia, gestational diabetes, increased inflammation, and preterm birth

**Address/Treat any contributing medical conditions:**

- RLS
- Sleep apnea
- Nighttime GERD
- Back pain

**Assess/Treat any comorbid mental health conditions:**

- Depression
- Anxiety
- Bipolar disorder
- PTSD (nightmares)
- Substance use

**Psychological/Behavioral Interventions – first line treatment**

- **Sleep hygiene**
  - Regular sleep schedule in calm, dark environment
  - Bed should be only for sleep (avoid screen use in bed)
  - Eliminate caffeine after noon

- **Pregnancy comfort measures**
  - Use pillows to take pressure off knees/back
  - Reduce liquid intake in evenings to minimize nighttime trips to bathroom

- **Cognitive Behavioral Therapy for Insomnia**

- **Exercise** (at least a few hours or longer before bed) – associated with longer sleep continuity in pregnancy

- **Postpartum**
  - Ensure adequate time for sleep – split infant night care between caregivers (use formula/pump so others can assist with feeding)
  - Ask about bed-sharing with infant which can interfere with sleep and recommend avoiding, especially if using sedating medications.

**If hypnotic medications are necessary – use low dose for short period along with behavioral interventions**

See medication chart for details on medications
In the perinatal period, insomnia medications can play a crucial role in managing sleep disorders. This table outlines various medications, their use in pregnancy and lactation, dosages, and potential side effects.

### Benzodiazepines

Lorazepam is preferred among benzodiazepines due to its safety profile during pregnancy and breastfeeding. Although benzodiazepines are generally considered safe, there is a risk of spontaneous abortion and preterm birth.

**FDA boxed warnings in general population:**
- Abuse, misuse, addiction, physical dependence, and withdrawal
- Opiate and benzodiazepine combination

**Side effects:**
- Sedation, poor coordination, risk of falls, memory impairment

### Nonbenzodiazepine Benzodiazepine Receptor Agonists

*Zolpidem* is preferred among non-benzodiazepines as it is associated with increased risk of falls and impaired cognitive function. It may also cause complex sleep behaviors such as sleepwalking, sleep driving, and sleep cooking.

**Complex Sleep Behaviors:**
- Sleepwalking
- Sleep driving
- Sleep cooking

### Antihistamines

Doxylamine, Hydroxyzine, and Diphenhydramine are antihistamines commonly used to treat insomnia. These medications can pass into breastmilk and may cause sedation, dizziness, impaired coordination, GI distress, and thickened bronchial secretions.
<table>
<thead>
<tr>
<th>Medication</th>
<th>Pregnancy</th>
<th>Lactation</th>
<th>Dose</th>
<th>Side Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Melatonin</td>
<td>Recommend avoiding in pregnancy until more data is available since exogenous melatonin could theoretically interfere with fetal circadian rhythms.</td>
<td>Melatonin is a normal component of breastmilk, but it is unclear the effect of exogenous melatonin. There was a case report of bleeding possibly related to melatonin.</td>
<td>-</td>
<td>*vivid dreams&lt;br&gt;*irritability&lt;br&gt;*headache&lt;br&gt;*sedation</td>
</tr>
<tr>
<td>Trazodone</td>
<td>Very limited data in pregnancy, but not expected to increase risk of congenital malformations</td>
<td>Limited data, but produces low levels in breastmilk and not expected to cause adverse effects</td>
<td>25-100mg</td>
<td>*drowsiness&lt;br&gt;*dizziness&lt;br&gt;*orthostatic hypotension&lt;br&gt;*GI symptoms</td>
</tr>
<tr>
<td>Mirtazapine</td>
<td>*antidepressant – consider in patients with insomnia comorbid with depression. Can also help with nausea&lt;br&gt; Limited data in pregnancy, but does not appear to be associated with increased risk of congenital malformations. There are conflicting reports about slight possible increase in spontaneous abortion, preterm and low birth weight. Also risk of postnatal adaptation.</td>
<td>Limited data, but doses of up to 120mg produce low levels in breast milk and not expected to cause adverse effects</td>
<td>7.5mg – 15mg (for insomnia, up to 45mg for depression)</td>
<td>*somnolence&lt;br&gt;*increased appetite&lt;br&gt;*constipation</td>
</tr>
<tr>
<td>Quetiapine</td>
<td>*due to side effects, recommend not using for insomnia alone, unless there is another indication for quetiapine (psychosis, bipolar disorder, antidepressant augmentation, treatment refractory anxiety)&lt;br&gt; *based on limited data, no increased risk of congenital malformations.&lt;br&gt; *possible increased risk of gestational diabetes&lt;br&gt; *FDA warning for all atypical antipsychotics (including quetiapine): 3rd trimester exposure increases risk of adverse effects in infant – EPS, sedation, breathing and feeding difficulties, sedation, agitation, tremor</td>
<td>Doses of up to 400mg produce low levels in breastmilk</td>
<td>*depends on indication (doses can range from 25mg – 800mg)</td>
<td>*FDA warning for all atypical antipsychotics: 3rd trimester exposure increases risk of adverse effects in infant – EPS, sedation, breathing and feeding difficulties, sedation, agitation, tremor&lt;br&gt; *side effects</td>
</tr>
</tbody>
</table>

The following medications for insomnia have no data in human pregnancy and lactation and thus should be avoided if possible: [suvorexant](#), [lemborexant](#), [ramelteon](#)
Sleep Resources

VA based CBT-I app:
https://mobile.va.gov/app/cbt-i-coach

Patient handout on pregnancy and sleep:
https://www.sleepfoundation.org/pregnancy
Substance Use in Pregnancy

Nadejda Bespalova, MD
## Substance Use in Pregnancy

### Screening, Brief Intervention, Referral to Treatment (SBIRT) model

All pregnant people should be screened for substance use at the first prenatal or preconception counseling visit (NIDA Quick Screen, 4 Ps)

### Rates of Use by Pregnant Patients

- Approximately 15% tobacco/nicotine, 9% alcohol, 5% illicit substances

### Negative Screen – no current use, low-level use prior to pregnancy

- Provide education – recommendation is to avoid alcohol, tobacco, cannabis, and illicit substances in pregnancy
- Offer MotherToBaby fact sheets (available for most commonly used substances at [https://mothertobaby.org/fact-sheets/](https://mothertobaby.org/fact-sheets/))

### Positive Screen – current use and/or history of heavy use or SUD diagnosis

- Further Assessment
  - Open-ended questions, avoid judgmental language
  - “What substances have you been using in the last 2-3 months?”
  - “How is substance use affecting your life?”
  - “Are you currently in treatment or have you had prior treatment?”
  - If using currently:
    - “How often are you using each substance and how much at a time?”
    - “How are you using these substances?” (ingesting, smoking, injecting)

### Currently Using Substances – Brief Intervention

- “Is it okay if we talk more about this?”
- “Would you be interested in help quitting/decreasing use?”
- “How ready are you to make this change on a scale from 1 to 10?”
- “How confident are you that you can make this change on a scale from 1 to 10?”

### Not Currently Misusing Substances – high risk history only or currently engaged in treatment

- If engaged in treatment – coordinate with SUD treatment provider, encourage continuing engagement

### Referral to Treatment

- Provide medications if possible/indicated (see attached)
- Consider referral to treatment program (outpatient, intensive outpatient, inpatient) — resources attached
- Warm handoff recommended

### Risks of Substance Misuse in Pregnancy

- Overdose – make sure patient has Narcan kit [https://stopoverdose.org/](https://stopoverdose.org/)
- Lower engagement with appropriate prenatal care
- Infection with injection use
- Legal problems/loss of parental rights
- Risks to pregnancy/child depend on substance and frequency/amounts

### Plan and Follow Up – Collaborative with Patient

- If referred out follow up with patient to ensure they made connection
- Repeat screen at least every trimester
- Ask about cravings
- Screen for comorbid mental health conditions
- Make sure patient has Narcan kit if using opioids (including prescription) or any illicit substances given high risk of fentanyl contamination
- Call Perinatal PCL with questions
Substance Use Screening

**NIDA Quick Screen:** [https://www.drugabuse.gov/sites/default/files/pdf/nmassist.pdf](https://www.drugabuse.gov/sites/default/files/pdf/nmassist.pdf)

**4 P’s for Substance Abuse:**

1. Have you ever used drugs or alcohol during Pregnancy?
2. Have you had a problem with drugs or alcohol in the Past?
3. Does your Partner have a problem with drugs or alcohol?
4. Do you consider one of your Parents to be an addict or alcoholic?

**Scoring:** Any “yes” should be used to trigger further discussion about drug or alcohol use.

**-Treatment Resources in Washington State:**

WA Recovery Helpline: [https://www.warecoveryhelpline.org/](https://www.warecoveryhelpline.org/)

SUD Treatment with Medicaid: [https://www.hca.wa.gov/free-or-low-cost-health-care/i-need-behavioral-health-support/substance-use-treatment](https://www.hca.wa.gov/free-or-low-cost-health-care/i-need-behavioral-health-support/substance-use-treatment)


Parent-Child Assistance Program (PCAP): [https://depts.washington.edu/pcapuw/](https://depts.washington.edu/pcapuw/)

**-Peer Support:**

Alcoholic/Narcotics Anonymous: [www.aa.org](http://www.aa.org); [www.na.org](http://www.na.org)

SMART Recovery: [www.smartrecovery.org](http://www.smartrecovery.org)

**-Nicotine cessation:**

Quit for Two: [https://women.smokefree.gov/pregnancy-motherhood/quit-smoking-while-pregnant/quit-for-two](https://women.smokefree.gov/pregnancy-motherhood/quit-smoking-while-pregnant/quit-for-two)
Selecting a Medication for Opioid Use Disorder in Pregnancy

Is the patient currently on a medication for opioid use disorder?

<table>
<thead>
<tr>
<th>YES</th>
<th>NO</th>
</tr>
</thead>
<tbody>
<tr>
<td>*Avoiding changing medication during pregnancy</td>
<td>*What has worked in the past?</td>
</tr>
<tr>
<td>*Monitor patient closely, ask about subjective medication efficacy, withdrawal symptoms, cravings</td>
<td>*What is readily available (may depend on treatment setting)?</td>
</tr>
<tr>
<td>*May require increase in total daily dose or frequency (especially methadone) in pregnancy</td>
<td>*What does the patient prefer?</td>
</tr>
<tr>
<td></td>
<td>*Review below with patient</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Considerations</th>
<th>Buprenorphine</th>
<th>Methadone</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prescribing setting</td>
<td>Office-based</td>
<td>Through Opioid Treatment Programs (pregnant patient have priority for access)</td>
</tr>
<tr>
<td>Dosing in pregnancy</td>
<td>May need to be increased</td>
<td>May need to be increased and converted from daily to twice per day</td>
</tr>
<tr>
<td>Risk of drug-drug interactions and QTc prolongation</td>
<td>Lower</td>
<td>Higher</td>
</tr>
<tr>
<td>Risk of overdose</td>
<td>Lower</td>
<td>Higher</td>
</tr>
<tr>
<td>Risk of sedation</td>
<td>Lower</td>
<td>Higher</td>
</tr>
<tr>
<td>Treatment retention</td>
<td>Lower</td>
<td>Higher</td>
</tr>
<tr>
<td>Risk of NOWS</td>
<td>Lower</td>
<td>Higher</td>
</tr>
<tr>
<td>Need to be in withdrawal to start</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>*low-dose (micro) induction is a way to avoid this</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Breastfeeding</td>
<td>Breastfeeding ok (and should be encouraged to decrease NOWS) if no other contraindications</td>
<td>Breastfeeding ok (and should be encouraged to decrease NOWS) if no other contraindications</td>
</tr>
</tbody>
</table>
Terms to Avoid: | Instead Use:
---|---
Alcoholic/drug addict/drug abuser | Person who uses substances
Addicted baby/born addicted | Child affected by maternal opioid use/Neonatal Opioid Withdrawal
Drug problem | Risky use/nonmedical use
Drug of choice | Substances used
Clean/dirty urine | Positive/Negative/Aberrant
Substitution/Replacement therapy | Medication for SUD/OUD, Medication-Assisted Treatment

Contact Perinatal PCL with questions:
Call 877-725-4666 or email ppcl@uw.edu

References:

